<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1194" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1194/" /><meta name="ncbi_pagename" content="Hereditary Transthyretin Amyloidosis - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Hereditary Transthyretin Amyloidosis - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Hereditary Transthyretin Amyloidosis" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/12/20" /><meta name="citation_author" content="Yoshiki Sekijima" /><meta name="citation_pmid" content="20301373" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1194/" /><meta name="citation_keywords" content="Familial Amyloid Polyneuropathy" /><meta name="citation_keywords" content="Familial Transthyretin Amyloidosis" /><meta name="citation_keywords" content="Hereditary ATTR Amyloidosis" /><meta name="citation_keywords" content="Hereditary ATTR Amyloidosis" /><meta name="citation_keywords" content="Familial Amyloid Polyneuropathy" /><meta name="citation_keywords" content="Familial Transthyretin Amyloidosis" /><meta name="citation_keywords" content="ATTR Cardiac Amyloidosis" /><meta name="citation_keywords" content="ATTR Leptomeningeal/CNS Amyloidosis" /><meta name="citation_keywords" content="ATTR Amyloid Neuropathy" /><meta name="citation_keywords" content="Transthyretin" /><meta name="citation_keywords" content="TTR" /><meta name="citation_keywords" content="Hereditary Transthyretin Amyloidosis" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Hereditary Transthyretin Amyloidosis" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Yoshiki Sekijima" /><meta name="DC.Date" content="2018/12/20" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1194/" /><meta name="description" content="Hereditary transthyretin (ATTR) amyloidosis is characterized by a slowly progressive peripheral sensorimotor and/or autonomic neuropathy as well as non-neuropathic changes of cardiomyopathy, nephropathy, vitreous opacities, and CNS amyloidosis. The disease usually begins in the third to fifth decade in persons from endemic foci in Portugal and Japan; onset is later in persons from other areas. Typically, sensory neuropathy starts in the lower extremities with paresthesias and hypesthesias of the feet, followed within a few years by motor neuropathy. In some persons, particularly those with early-onset disease, autonomic neuropathy is the first manifestation of the condition; findings can include: orthostatic hypotension, constipation alternating with diarrhea, attacks of nausea and vomiting, delayed gastric emptying, sexual impotence, anhidrosis, and urinary retention or incontinence. Cardiac amyloidosis is mainly characterized by progressive cardiomyopathy. Individuals with leptomeningeal amyloidosis may have the following CNS findings: dementia, psychosis, visual impairment, headache, seizures, motor paresis, ataxia, myelopathy, hydrocephalus, or intracranial hemorrhage." /><meta name="og:title" content="Hereditary Transthyretin Amyloidosis" /><meta name="og:type" content="book" /><meta name="og:description" content="Hereditary transthyretin (ATTR) amyloidosis is characterized by a slowly progressive peripheral sensorimotor and/or autonomic neuropathy as well as non-neuropathic changes of cardiomyopathy, nephropathy, vitreous opacities, and CNS amyloidosis. The disease usually begins in the third to fifth decade in persons from endemic foci in Portugal and Japan; onset is later in persons from other areas. Typically, sensory neuropathy starts in the lower extremities with paresthesias and hypesthesias of the feet, followed within a few years by motor neuropathy. In some persons, particularly those with early-onset disease, autonomic neuropathy is the first manifestation of the condition; findings can include: orthostatic hypotension, constipation alternating with diarrhea, attacks of nausea and vomiting, delayed gastric emptying, sexual impotence, anhidrosis, and urinary retention or incontinence. Cardiac amyloidosis is mainly characterized by progressive cardiomyopathy. Individuals with leptomeningeal amyloidosis may have the following CNS findings: dementia, psychosis, visual impairment, headache, seizures, motor paresis, ataxia, myelopathy, hydrocephalus, or intracranial hemorrhage." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1194/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/tfap/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1194/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88EA39E03FE36100000000087602C7.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1194_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1194_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/hsp/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/hyperek/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1194_"><span class="title" itemprop="name">Hereditary Transthyretin Amyloidosis</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Familial Amyloid Polyneuropathy, Familial Transthyretin Amyloidosis, Hereditary ATTR Amyloidosis</div><p class="contrib-group"><span itemprop="author">Yoshiki Sekijima</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1194_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1194_ai__"><div class="contrib half_rhythm"><span itemprop="author">Yoshiki Sekijima</span>, MD, PhD<div class="affiliation small">Department of Medicine &#x02013;Neurology &#x00026; Rheumatology<br />Shinshu University School of Medicine<br />Matsumoto, Japan<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="pj.ca.u-uhsnihs@amijikes" class="oemail">pj.ca.u-uhsnihs@amijikes</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">November 5, 2001</span>; Last Update: <span itemprop="dateModified">December 20, 2018</span>.</p><p><em>Estimated reading time: 34 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="tfap.Summary" itemprop="description"><h2 id="_tfap_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Hereditary transthyretin (ATTR) amyloidosis is characterized by a slowly progressive peripheral sensorimotor and/or autonomic neuropathy as well as non-neuropathic changes of cardiomyopathy, nephropathy, vitreous opacities, and CNS amyloidosis. The disease usually begins in the third to fifth decade in persons from endemic foci in Portugal and Japan; onset is later in persons from other areas. Typically, sensory neuropathy starts in the lower extremities with paresthesias and hypesthesias of the feet, followed within a few years by motor neuropathy. In some persons, particularly those with early-onset disease, autonomic neuropathy is the first manifestation of the condition; findings can include: orthostatic hypotension, constipation alternating with diarrhea, attacks of nausea and vomiting, delayed gastric emptying, sexual impotence, anhidrosis, and urinary retention or incontinence. Cardiac amyloidosis is mainly characterized by progressive cardiomyopathy. Individuals with leptomeningeal amyloidosis may have the following CNS findings: dementia, psychosis, visual impairment, headache, seizures, motor paresis, ataxia, myelopathy, hydrocephalus, or intracranial hemorrhage.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of hereditary ATTR amyloidosis is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with characteristic clinical features, amyloid deposits identified on biopsy that bind to anti-TTR antibodies, and identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TTR</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Orthotopic liver transplantation (OTLX) halts the progression of peripheral and/or autonomic neuropathy; OTLX is recommended in individuals younger than age 60 years with: (1) disease duration less than five years, (2) polyneuropathy restricted to the lower extremities or with autonomic neuropathy alone, and (3) no significant cardiac or renal dysfunction. Additional treatment options include TTR tetramer stabilizers and <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-silencing therapies. Surgery is indicated for carpal tunnel syndrome, vitrectomy for vitreous involvement, and surgical treatment for glaucoma. In those with sick sinus syndrome or second-degree or third-degree AV block, a cardiac pacemaker may be indicated.</p><p><i>Surveillance:</i> Serial nerve conduction studies to monitor polyneuropathy; serial electrocardiogram, echocardiography, and serum B-type natriuretic peptide levels to monitor cardiomyopathy and conduction block; follow modified body mass index to monitor nutritional status.</p><p><i>Agents/circumstances to avoid</i>: Local heating appliances, such as hot-water bottles, which can cause low-temperature burn injury in those with decreased temperature and pain perception.</p><p><i>Evaluation of relatives at risk:</i> If the family-specific <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> ensures early diagnosis and treatment. If the <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> variant is not known, clinical evaluations ensure early diagnosis and treatment.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Hereditary ATTR amyloidosis is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Each child of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual (who is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for one <i>TTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>) has a 50% chance of inheriting the <i>TTR</i> variant. For affected individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for <i>TTR</i> pathogenic variants:</p><ul><li class="half_rhythm"><div>Each sib is at a 50% risk of inheriting one <i>TTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and a 25% risk of inheriting two <i>TTR</i> pathogenic variants;</div></li><li class="half_rhythm"><div>All offspring will inherit a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li></ul><p>Prenatal testing for pregnancies at increased risk is possible if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the family. Requests for prenatal testing for adult-onset conditions that (like hereditary ATTR amyloidosis) do not affect intellect and have some treatment available are not common.</p></div></div><div id="tfap.GeneReview_Scope"><h2 id="_tfap_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="tfap.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1194/table/tfap.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tfap.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tfap.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hereditary Transthyretin (ATTR) Amyloidosis: Included Phenotypes</th></tr></thead><tbody><tr><td headers="hd_h_tfap.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>ATTR amyloid neuropathy</div></li><li class="half_rhythm"><div>ATTR cardiac amyloidosis</div></li><li class="half_rhythm"><div>ATTR leptomeningeal/CNS amyloidosis</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#tfap.Nomenclature">Nomenclature</a>.</p></div></dd></dl></div></div></div></div><div id="tfap.Diagnosis"><h2 id="_tfap_Diagnosis_">Diagnosis</h2><div id="tfap.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Hereditary transthyretin (ATTR) amyloidosis <b>should be suspected</b> in adults with the following clinical features, family history, and histopathology.</p><p><b>Clinical features.</b> Slowly progressive sensorimotor and/or autonomic neuropathy that is frequently accompanied by one or more of the following:</p><ul><li class="half_rhythm"><div>Cardiac conduction blocks</div></li><li class="half_rhythm"><div>Cardiomyopathy</div></li><li class="half_rhythm"><div>Nephropathy</div></li><li class="half_rhythm"><div>Vitreous opacities</div></li><li class="half_rhythm"><div>Glaucoma</div></li></ul><p><b>Family history.</b> Consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance</p><p>Note: While family history supports the diagnosis, absence of other <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in the family does not preclude the diagnosis of hereditary ATTR amyloidosis, especially in persons older than age 50 years.</p><p><b>Histopathology</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Tissue biopsy to identify amyloid deposits.</b> Tissues suitable for biopsy include: subcutaneous fatty tissue of the abdominal wall, skin, gastric or rectal mucosa, sural nerve, and peritendinous fat from specimens obtained at carpal tunnel surgery. With Congo red staining, amyloid deposits show a characteristic yellow-green birefringence under polarized light.</div><div class="half_rhythm">Note: Sensitivity of endoscopic biopsy of gastrointestinal mucosa is approximately 85%; biopsy of the sural nerve is less sensitive because amyloid deposition is often patchy [<a class="bk_pop" href="#tfap.REF.hund.2001.431">Hund et al 2001</a>, <a class="bk_pop" href="#tfap.REF.koike.2004.129">Koike et al 2004</a>, <a class="bk_pop" href="#tfap.REF.vital.2004.232">Vital et al 2004</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Immunohistochemistry of tissue biopsies with anti-TTR antibodies</b> to identify amyloid deposits associated with ATTR amyloidosis</div></li></ul></div><div id="tfap.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of hereditary ATTR amyloidosis <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the above clinical features, biopsy showing amyloid deposits that bind to anti-TTR antibodies, and identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TTR</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1194/table/tfap.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figtfapTmoleculargenetictestingusedin" rid-ob="figobtfapTmoleculargenetictestingusedin">Table 1</a>).</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>TTR</i> detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications are not detected.</div><div class="half_rhythm">Note: (1)Targeted analysis for pathogenic variants can be performed first for the most common <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">c.148G&#x0003e;A</a> (<a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a>). (2) Since hereditary ATTR amyloidosis occurs through a <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> mechanism and large intragenic <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> or <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> has not been reported, testing for intragenic deletions or duplication is unlikely to identify a disease-causing variant.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>TTR</i> and other genes of interest (see <a href="#tfap.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="tfap.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Hereditary Transthyretin (ATTR) Amyloidosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1194/table/tfap.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tfap.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tfap.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_tfap.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_tfap.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_tfap.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>TTR</i></td><td headers="hd_h_tfap.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_tfap.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;99%&#x000a0;<sup>4,&#x000a0;5</sup></td></tr><tr><td headers="hd_h_tfap.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_tfap.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported&#x000a0;<sup>7</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="tfap.TF.1.1"><p class="no_margin">See <a href="/books/NBK1194/#tfap.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="tfap.TF.1.2"><p class="no_margin">See <a href="#tfap.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="tfap.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="tfap.TF.1.4"><p class="no_margin">The most common <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">c.148G&#x0003e;A</a> (<a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a>), has been identified in many individuals of different ethnic backgrounds; it is found in large clusters in Portugal, Sweden, and Japan.</p></div></dd><dt>5. </dt><dd><div id="tfap.TF.1.5"><p class="no_margin">The <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> has four exons; all pathogenic variants identified to date are in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2, 3, or 4.</p></div></dd><dt>6. </dt><dd><div id="tfap.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>7. </dt><dd><div id="tfap.TF.1.7"><p class="no_margin">Since hereditary ATTR amyloidosis occurs through a <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> mechanism and large intragenic <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> or <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> has not been reported, testing for intragenic deletions or duplication is unlikely to identify a disease-causing variant.</p></div></dd></dl></div></div></div></div></div><div id="tfap.Clinical_Characteristics"><h2 id="_tfap_Clinical_Characteristics_">Clinical Characteristics</h2><div id="tfap.Clinical_Description"><h3>Clinical Description</h3><p>Clinical features of hereditary transthyretin (ATTR) amyloidosis can include peripheral sensorimotor neuropathy and autonomic neuropathy, as well as non-neuropathic changes (cardiomyopathy, nephropathy, vitreous opacities, and CNS amyloidosis) (see <a class="figpopup" href="/books/NBK1194/table/tfap.T.phenotypes_associated_with_heredi/?report=objectonly" target="object" rid-figpopup="figtfapTphenotypesassociatedwithheredi" rid-ob="figobtfapTphenotypesassociatedwithheredi">Table 2</a>).</p><div id="tfap.T.phenotypes_associated_with_heredi" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Phenotypes Associated with Hereditary Transthyretin (ATTR) Amyloidosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1194/table/tfap.T.phenotypes_associated_with_heredi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tfap.T.phenotypes_associated_with_heredi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_1_2" style="text-align:left;vertical-align:middle;">Representative Genotype</th></tr><tr><th headers="hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_1_1" id="hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_2_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Type</th><th headers="hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_1_1" id="hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Features</th></tr></thead><tbody><tr><td headers="hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_1_1 hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ATTR amyloid neuropathy<br />(<a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> amyloid polyneuropathy)</td><td headers="hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_1_1 hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early:
<ul><li class="half_rhythm"><div>Sensorimotor polyneuropathy of the legs</div></li><li class="half_rhythm"><div>Carpal tunnel syndrome</div></li><li class="half_rhythm"><div>Autonomic dysfunction</div></li><li class="half_rhythm"><div>Constipation &#x00026;/or diarrhea</div></li><li class="half_rhythm"><div>Impotence</div></li></ul>
Late:
<ul><li class="half_rhythm"><div>Cardiomyopathy</div></li><li class="half_rhythm"><div>Vitreous opacities</div></li><li class="half_rhythm"><div>Glaucoma</div></li><li class="half_rhythm"><div>Nephropathy</div></li><li class="half_rhythm"><div>CNS symptoms</div></li></ul>
</td><td headers="hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a>&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_1_1 hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ATTR cardiac amyloidosis<br />(<a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> amyloid cardiomyopathy)</td><td headers="hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_1_1 hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Cardiomegaly</div></li><li class="half_rhythm"><div>Conduction block</div></li><li class="half_rhythm"><div>Arrhythmia</div></li><li class="half_rhythm"><div>Anginal pain</div></li><li class="half_rhythm"><div>Congestive heart failure</div></li><li class="half_rhythm"><div>Sudden death</div></li></ul>
</td><td headers="hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val142Ile</a></td></tr><tr><td headers="hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_1_1 hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ATTR leptomeningeal amyloidosis / cerebral amyloid angiopathy</td><td headers="hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_1_1 hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Transient focal neurologic episodes</div></li><li class="half_rhythm"><div>Hemorrhage (intracerebral &#x00026;/or subarachnoid)</div></li><li class="half_rhythm"><div>Dementia</div></li><li class="half_rhythm"><div>Ataxia</div></li><li class="half_rhythm"><div>Spasticity</div></li><li class="half_rhythm"><div>Seizures</div></li><li class="half_rhythm"><div>Psychosis</div></li><li class="half_rhythm"><div>Hydrocephalus</div></li></ul>
</td><td headers="hd_h_tfap.T.phenotypes_associated_with_heredi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Asp38Gly</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="tfap.TF.2.1"><p class="no_margin">Historic protein numbering was based on the mature protein after cleavage of a 20-amino-acid signal sequence (i.e., <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a> would be referred to as Val30Met). Standard nomenclature uses numbering beginning at the Met initiation codon. Variants reported in older literature may use historic nomenclature.</p></div></dd></dl></div></div></div><p><b>Neuropathy.</b> The cardinal feature of ATTR-amyloid neuropathy is slowly progressive sensorimotor and autonomic neuropathy [<a class="bk_pop" href="#tfap.REF.ando.2005.1057">Ando et al 2005</a>]. Typically, sensory neuropathy starts in the lower extremities and is followed by motor neuropathy within a few years. The initial signs of this sensory neuropathy are paresthesias (sense of burning, shooting pain) and hypesthesias of the feet. Temperature and pain sensation are impaired earlier than vibration and position sensation. By the time sensory neuropathy progresses to the level of the knees, the hands have usually become <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. In the full-blown stage of the disease, sensory loss, muscle atrophy, and weakness of the extremities show a glove and stocking distribution. Foot drop, wrist drop, and disability of the hands and fingers are common symptoms of motor neuropathy.</p><p>Autonomic neuropathy may occur as the first clinical symptom of the disease. The symptoms of autonomic dysfunction include: orthostatic hypotension [<a class="bk_pop" href="#tfap.REF.vita.2005.259">Vita et al 2005</a>], constipation alternating with diarrhea, attacks of nausea and vomiting, delayed gastric emptying, sexual impotence, anhidrosis, and urinary retention or incontinence. Because of sensory loss and autonomic dysfunction, trophic ulcers on the lower extremities are common. Frequently, the autonomic neuropathy produces the most significant morbidity of the disorder.</p><p>The disease usually begins in the third, fourth, or fifth decade in persons from endemic foci in Portugal and Japan; onset is later in persons from other areas. The following findings indicate that age at onset varies greatly even within ethnically identical populations with the same <i>TTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>:</p><ul><li class="half_rhythm"><div>For persons of Japanese ancestry with the <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a> variant who are related to two large endemic foci (Ogawa village and Arao city), the mean age at onset is 40.1&#x000b1;12.8 years (range 22-74 years) [<a class="bk_pop" href="#tfap.REF.nakazato.1998.528">Nakazato 1998</a>].</div></li><li class="half_rhythm"><div>For persons of Japanese ancestry with <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a> who are unrelated to the two large endemic foci, the mean age at onset is much later (62.7&#x000b1;6.6 years) (range 52-80 years) [<a class="bk_pop" href="#tfap.REF.misu.1999.1951">Misu et al 1999</a>, <a class="bk_pop" href="#tfap.REF.ikeda.2002.1001">Ikeda et al 2002</a>].</div></li><li class="half_rhythm"><div>For persons of Portuguese ancestry with the <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a> variant, the mean age at onset is 33.5 &#x000b1;9.4 years (range 17-78 years).</div></li><li class="half_rhythm"><div>For persons of Swedish, French, or British ancestry, the mean age at onset is much later than that in individuals of Japanese or Portuguese ancestry [<a class="bk_pop" href="#tfap.REF.plant_bordeneuve.1998.708">Plant&#x000e9;-Bordeneuve et al 1998</a>].</div></li></ul><p>Sensorimotor neuropathy and autonomic neuropathy progress over ten to 20 years. Various types of cardiac conduction block frequently appear. Cachexia is a common feature at the late stage of the disease. Affected individuals usually die of cardiac failure, renal failure, or infection.</p><p>Individuals with specific <i>TTR</i> variants (e.g., <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Leu78His</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Leu78Arg</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Lys90Asn</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Ile104Ser</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Ile127Val</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Tyr134His</a>) tend to develop carpal tunnel syndrome as an initial symptom [<a class="bk_pop" href="#tfap.REF.nakazato.1998.528">Nakazato 1998</a>, <a class="bk_pop" href="#tfap.REF.connors.2000.54">Connors et al 2000</a>, <a class="bk_pop" href="#tfap.REF.benson.2001">Benson 2001</a>, <a class="bk_pop" href="#tfap.REF.hund.2001.431">Hund et al 2001</a>, <a class="bk_pop" href="#tfap.REF.connors.2003.160">Connors et al 2003</a>].</p><p>Sensorimotor neuropathy and autonomic neuropathy are accompanied by visceral involvement. Cardiomyopathy (e.g., cardiac failure, arrhythmia, conduction block), ophthalmopathy (e.g., vitreous opacities, glaucoma), nephropathy, and/or CNS manifestations (e.g., transient focal neurologic episodes, intracerebral and/or subarachnoid hemorrhages) are frequently seen in the advanced stage of the disease.</p><p><b>Non-neuropathic amyloidosis.</b> Individuals with hereditary ATTR amyloidosis do not necessarily present with polyneuropathy. Cardiac amyloidosis and leptomeningeal amyloidosis are well-known non-neuropathic forms of hereditary ATTR amyloidosis that are associated with specific <i>TTR</i> variants. In these types of hereditary ATTR amyloidosis, polyneuropathy is absent or, if present, less evident. Approximately one third of the TTR protein variants are accompanied by vitreous opacities.</p><p><b>Cardiac amyloidosis,</b> mainly characterized by progressive cardiomyopathy, has been associated with more than two thirds of <i>TTR</i> pathogenic variants (see <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">Table 6</a>) [<a class="bk_pop" href="#tfap.REF.nakazato.1998.528">Nakazato 1998</a>, <a class="bk_pop" href="#tfap.REF.benson.2001">Benson 2001</a>, <a class="bk_pop" href="#tfap.REF.saraiva.2001.493">Saraiva 2001</a>, <a class="bk_pop" href="#tfap.REF.connors.2003.160">Connors et al 2003</a>, <a class="bk_pop" href="#tfap.REF.hattori.2003.229">Hattori et al 2003</a>, <a class="bk_pop" href="#tfap.REF.benson.2007.411">Benson &#x00026; Kincaid 2007</a>]. In some families with specific <i>TTR</i> variants, such as <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Asp38Asn</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val40Ile</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Pro44Ser</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Ala65Thr</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Ala65Ser</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.His76Arg</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Gly77Arg</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Ile88Leu</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Ala101Thr</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Ala101Val</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.His108Arg</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Glu112Lys</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Arg123Ser</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Leu131Met</a>, or <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val142Ile</a>, cardiomyopathy without peripheral neuropathy is a main feature of the disease.</p><p>Cardiac amyloidosis is usually late onset. Most individuals develop cardiac symptoms after age 50 years; cardiac amyloidosis generally presents with restrictive cardiomyopathy. The typical electrocardiogram shows a pseudoinfarction pattern with prominent Q wave in leads II, III, <sub>a</sub>V<sub>F</sub>, and V<sub>1</sub>-V<sub>3</sub>, presumably resulting from dense amyloid deposition in the anterobasal or anteroseptal wall of the left ventricle. The echocardiogram reveals left ventricular hypertrophy with preserved systolic function. The thickened walls present "a granular sparkling appearance."</p><p>Among the variants responsible for cardiac amyloidosis, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val142Ile</a> is notable for its prevalence in African Americans. Approximately 3.0%-3.9% of African Americans are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for p.Val142Ile [<a class="bk_pop" href="#tfap.REF.yamashita.2005.127">Yamashita et al 2005</a>]. The high frequency of p.Val142Ile partly explains the observation that in individuals in the US older than age 60 years, cardiac amyloidosis is four times more common among blacks than whites [<a class="bk_pop" href="#tfap.REF.jacobson.1997.466">Jacobson et al 1997</a>].</p><p><b>Leptomeningeal (oculoleptomeningeal) amyloidosis / cerebral amyloid angiopathy.</b> Amyloid deposition is seen in the pial and arachnoid membrane, as well as in the walls of vessels in the subarachnoid space associated with <i>TTR</i> pathogenic variants including p.Leu32Pro, p.Asp38Gly, p.Ala45Thr, p.Val50Gly, p.Ala56Pro, p.Gly73Glu, p.Gly73Ala, p.Phe84Ser, p.Tyr89His, or p.Tyr134Cys (see <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">Table 6</a>) [<a class="bk_pop" href="#tfap.REF.petersen.1997.307">Petersen et al 1997</a>, <a class="bk_pop" href="#tfap.REF.nakazato.1998.528">Nakazato 1998</a>, <a class="bk_pop" href="#tfap.REF.brett.1999.183">Brett et al 1999</a>, <a class="bk_pop" href="#tfap.REF.mascalchi.1999.1498">Mascalchi et al 1999</a>, <a class="bk_pop" href="#tfap.REF.uemichi.1999.1152">Uemichi et al 1999</a>, <a class="bk_pop" href="#tfap.REF.connors.2000.54">Connors et al 2000</a>, <a class="bk_pop" href="#tfap.REF.benson.2001">Benson 2001</a>, <a class="bk_pop" href="#tfap.REF.ellie.2001.135">Ellie et al 2001</a>, <a class="bk_pop" href="#tfap.REF.saraiva.2001.493">Saraiva 2001</a>, <a class="bk_pop" href="#tfap.REF.ikeda.2002.1001">Ikeda et al 2002</a>, <a class="bk_pop" href="#tfap.REF.blevins.2003.1625">Blevins et al 2003</a>, <a class="bk_pop" href="#tfap.REF.connors.2003.160">Connors et al 2003</a>, <a class="bk_pop" href="#tfap.REF.hammarstr_m.2003.6656">Hammarstr&#x000f6;m et al 2003</a>, <a class="bk_pop" href="#tfap.REF.sekijima.2003.409">Sekijima et al 2003</a>]. Amyloid in the blood vessels disappears as the vessels penetrate the brain parenchyma.</p><p>Individuals with leptomeningeal amyloidosis show CNS signs and symptoms including: transient focal neurologic episodes, dementia, psychosis, visual impairment, headache, seizures, motor paresis, ataxia, myelopathy, hydrocephalus, or intracranial hemorrhage.</p><p>When associated with vitreous amyloid deposits, leptomeningeal amyloidosis is known as <i>f</i>amilial <i>o</i>culo<i>l</i>epto<i>m</i>eningeal <i>a</i>myloidosis (FOLMA) [<a class="bk_pop" href="#tfap.REF.petersen.1997.307">Petersen et al 1997</a>, <a class="bk_pop" href="#tfap.REF.jin.2004.1463">Jin et al 2004</a>].</p><p>In leptomeningeal amyloidosis protein concentration in the cerebrospinal fluid is usually high, and gadolinium-enhanced MRI typically shows extensive enhancement of the surface of the brain, ventricles, and spinal cord [<a class="bk_pop" href="#tfap.REF.brett.1999.183">Brett et al 1999</a>].</p><p>Although meningeal biopsy is necessary to confirm amyloid deposition in the meninges, characteristic MRI findings and the presence of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TTR</i> strongly suggest this pathology [<a class="bk_pop" href="#tfap.REF.mitsuhashi.2004.265">Mitsuhashi et al 2004</a>]. CNS ATTR amyloid deposition can also be detected by amyloid PET, using Pittsburgh compound B (PiB) [<a class="bk_pop" href="#tfap.REF.sekijima.2016.773">Sekijima et al 2016</a>].</p><p><b>Ocular amyloidosis.</b> Ocular involvement, including vitreous opacity, glaucoma, dry eye, and ocular amyloid angiopathy, is common and occurs in most individuals with <i>TTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a> [<a class="bk_pop" href="#tfap.REF.ando.1997.295">Ando et al 1997</a>]. Vitreous opacification has been reported in approximately 20% of families with various <i>TTR</i> pathogenic variants, including p.Val50Met [<a class="bk_pop" href="#tfap.REF.benson.2001">Benson 2001</a>, <a class="bk_pop" href="#tfap.REF.connors.2003.160">Connors et al 2003</a>, <a class="bk_pop" href="#tfap.REF.kawaji.2004.257">Kawaji et al 2004</a>, <a class="bk_pop" href="#tfap.REF.benson.2007.411">Benson &#x00026; Kincaid 2007</a>]. Four of 43 individuals with the p.Val50Met variant developed vitreous amyloidosis as the first manifestation of hereditary ATTR amyloidosis [<a class="bk_pop" href="#tfap.REF.kawaji.2004.257">Kawaji et al 2004</a>]. In one case report, vitreous opacification was the only evidence of amyloid deposit caused by the <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Trp61Leu</a> variant [<a class="bk_pop" href="#tfap.REF.yazaki.2002.263">Yazaki et al 2002</a>].</p><p><b>Nephropathy.</b> The kidney is consistently involved with marked deposition of amyloid demonstrated at postmortem examination. Mild to severe renal involvement is usually seen in the advanced stage [<a class="bk_pop" href="#tfap.REF.haagsma.2004.44">Haagsma et al 2004</a>, <a class="bk_pop" href="#tfap.REF.lobato.2004.27">Lobato et al 2004</a>]. Renal involvement, including nephritic syndrome and progressive renal failure, occurs in about one third of individuals of Portuguese descent with early-onset hereditary ATTR amyloidosis caused by <i>TTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a> [<a class="bk_pop" href="#tfap.REF.lobato.2004.27">Lobato et al 2004</a>]; however, severe renal dysfunction rarely occurs in individuals with late-onset disease.</p><p><b>Other.</b> Amyloid deposition on the gastrointestinal tract wall, especially with involvement of the gastrointestinal autonomic nerves, is common [<a class="bk_pop" href="#tfap.REF.ikeda.1982.1364">Ikeda et al 1982</a>, <a class="bk_pop" href="#tfap.REF.ikeda.1983.1055">Ikeda et al 1983</a>]. Nodular cutaneous amyloidosis has been reported in an individual with the <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Tyr134His</a> variant [<a class="bk_pop" href="#tfap.REF.mochizuki.2001.105">Mochizuki et al 2001</a>]. Shortness of breath induced by diffuse pulmonary amyloid deposition has been reported in two individuals with the <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Asp58Ala</a> variant [<a class="bk_pop" href="#tfap.REF.yazaki.a">Yazaki et al 2000a</a>]. nemia with low erythropoietin has been reported in 25% of individuals [<a class="bk_pop" href="#tfap.REF.beir_o.2004.2004">Beir&#x000e3;o et al 2004</a>].</p></div><div id="tfap.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p><b>Heterozygotes.</b> Despite intensive investigation, few <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> have been detected.</p><p>The <a class="def" href="/books/n/gene/glossary/def-item/benign-variant/">benign variant</a> <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">c.416C&#x0003e;T</a> (<a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Thr139Met</a>) has a protective effect on amyloidogenesis in individuals who have the <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a> variant [<a class="bk_pop" href="#tfap.REF.hammarstr_m.2001.2459">Hammarstr&#x000f6;m et al 2001</a>, <a class="bk_pop" href="#tfap.REF.sebasti_o.2001.733">Sebasti&#x000e3;o et al 2001</a>].</p><p>Most <i>TTR</i> pathogenic variants result in peripheral and autonomic neuropathy; but some pathogenic variants have been associated with phenotypes in which peripheral or autonomic neuropathy is clinically absent or less prominent:</p><ul><li class="half_rhythm"><div class="half_rhythm">Cardiac amyloidosis is caused by <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Asp38Asn</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val40Ile</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Pro44Ser</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Ala65Thr</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">Ala65Ser</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.His76Arg</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Gly77Arg</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Ile88Leu</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Ala101Thr</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Ala101Val</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.His108Arg</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Glu112Lys</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Arg123Ser</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Leu131Met</a>, or <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val142Ile</a> [<a class="bk_pop" href="#tfap.REF.nakazato.1998.528">Nakazato 1998</a>, <a class="bk_pop" href="#tfap.REF.benson.2001">Benson 2001</a>, <a class="bk_pop" href="#tfap.REF.saraiva.2001.493">Saraiva 2001</a>, <a class="bk_pop" href="#tfap.REF.connors.2003.160">Connors et al 2003</a>, <a class="bk_pop" href="#tfap.REF.benson.2007.411">Benson &#x00026; Kincaid 2007</a>]. Peripheral and autonomic neuropathy are absent or less evident in persons with these variants.</div></li><li class="half_rhythm"><div class="half_rhythm">Leptomeningeal amyloidosis is associated with <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Leu32Pro</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Asp38Gly</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Ala45Thr</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Gly</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Ala56Pro</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Gly73Glu</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Gly73Ala</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Phe84Ser</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Tyr89His</a>, or <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Tyr134Cys</a> [<a class="bk_pop" href="#tfap.REF.petersen.1997.307">Petersen et al 1997</a>, <a class="bk_pop" href="#tfap.REF.nakazato.1998.528">Nakazato 1998</a>, <a class="bk_pop" href="#tfap.REF.brett.1999.183">Brett et al 1999</a>, <a class="bk_pop" href="#tfap.REF.mascalchi.1999.1498">Mascalchi et al 1999</a>, <a class="bk_pop" href="#tfap.REF.uemichi.1999.1152">Uemichi et al 1999</a>, <a class="bk_pop" href="#tfap.REF.connors.2000.54">Connors et al 2000</a>, <a class="bk_pop" href="#tfap.REF.benson.2001">Benson 2001</a>, <a class="bk_pop" href="#tfap.REF.ellie.2001.135">Ellie et al 2001</a>, <a class="bk_pop" href="#tfap.REF.saraiva.2001.493">Saraiva 2001</a>, <a class="bk_pop" href="#tfap.REF.ikeda.2002.1001">Ikeda et al 2002</a>, <a class="bk_pop" href="#tfap.REF.blevins.2003.1625">Blevins et al 2003</a>, <a class="bk_pop" href="#tfap.REF.connors.2003.160">Connors et al 2003</a>, <a class="bk_pop" href="#tfap.REF.hammarstr_m.2003.6656">Hammarstr&#x000f6;m et al 2003</a>, <a class="bk_pop" href="#tfap.REF.sekijima.2003.409">Sekijima et al 2003</a>].</div><div class="half_rhythm">It has been demonstrated that highly destabilized <i>TTR</i> variants induce leptomeningeal amyloidosis [<a class="bk_pop" href="#tfap.REF.hammarstr_m.2001.2459">Hammarstr&#x000f6;m et al 2001</a>, <a class="bk_pop" href="#tfap.REF.sekijima.2003.409">Sekijima et al 2003</a>, <a class="bk_pop" href="#tfap.REF.sekijima.2005.73">Sekijima et al 2005</a>].</div></li></ul><p><b>Homozygosity</b> for the <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a> variant has been reported in at least 19 individuals from 14 families [<a class="bk_pop" href="#tfap.REF.munarqu_s.2001.121">Munar-Qu&#x000e9;s et al 2001</a>, <a class="bk_pop" href="#tfap.REF.tojo.2008.796">Tojo et al 2008</a>]. Eight homozygotes for variants <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val142Ile</a> (5), <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Leu78His</a> (1), <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Phe84Leu</a> (1), and <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Ile88Leu</a> (1) have been reported [<a class="bk_pop" href="#tfap.REF.jacobson.1990.127">Jacobson et al 1990</a>, <a class="bk_pop" href="#tfap.REF.nichols.1991.175">Nichols et al 1991</a>, <a class="bk_pop" href="#tfap.REF.ferlini.1996.10">Ferlini et al 1996</a>, <a class="bk_pop" href="#tfap.REF.askanas.2000.544">Askanas et al 2000</a>, <a class="bk_pop" href="#tfap.REF.jacob.2007.127">Jacob et al 2007</a>, <a class="bk_pop" href="#tfap.REF.perfetto.2011.450">Perfetto et al 2011</a>].</p><p>Homozygotes present with a slightly more severe clinical course (higher incidence rate and earlier onset) than heterozygotes within the same family [<a class="bk_pop" href="#tfap.REF.tojo.2008.796">Tojo et al 2008</a>]; amyloid deposition is more widespread in homozygotes than in heterozygotes [<a class="bk_pop" href="#tfap.REF.yoshinaga.2004.56">Yoshinaga et al 2004</a>]. Most homozygotes are members of families characterized by incomplete <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of hereditary ATTR amyloidosis.</p></div><div id="tfap.Penetrance"><h3>Penetrance</h3><p>Because the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> for hereditary ATTR amyloidosis is not 100%, an individual with a <i>TTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may be symptom free until late adulthood. The penetrance may vary by variant, geographic region, or ethnic group.</p><p>The <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> appears to be much higher in individuals in endemic foci than outside of endemic foci [<a class="bk_pop" href="#tfap.REF.misu.1999.1951">Misu et al 1999</a>]. In Portugal, cumulative disease risk in individuals with the <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a> variant is estimated at 80% by age 50 and 91% by age 70 years, whereas the risk in French heterozygotes is 14% by age 50 and 50% by age 70 years [<a class="bk_pop" href="#tfap.REF.plant_bordeneuve.2003.e120">Plant&#x000e9;-Bordeneuve et al 2003</a>]. In Sweden, the penetrance is much lower: 1.7% by age 30, 5% by age 40, 11% by age 50, 22% by age 60, 36% by age 70, 52% by age 80, and 69% by age 90, respectively [<a class="bk_pop" href="#tfap.REF.hellman.2008.181">Hellman et al 2008</a>].</p><p>Some <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a> homozygotes remain asymptomatic.</p></div><div id="tfap.Nomenclature"><h3>Nomenclature</h3><p>Historic protein numbering was based on the mature protein after cleavage of a 20-amino-acid signal sequence (e.g., <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a> would be referred to as Val30Met). Standard nomenclature uses numbering beginning at the Met initiation codon. Variants reported in older literature may use historic nomenclature.</p><p>The neuropathy associated with <i>TTR</i> pathogenic variants, now called hereditary ATTR amyloidosis, was formerly referred to as one of the following:</p><ul><li class="half_rhythm"><div>Familial amyloid polyneuropathy type I (or the Portuguese-Swedish-Japanese type)</div></li><li class="half_rhythm"><div>Familial amyloid polyneuropathy type II (or the Indiana/Swiss or Maryland/German type)</div></li></ul></div><div id="tfap.Prevalence"><h3>Prevalence</h3><p>The <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, found worldwide, is the most widely studied <i>TTR</i> variant and is responsible for the well-known large foci of individuals with TTR amyloid polyneuropathy in Portugal, Sweden, and Japan. Numerous families with various pathogenic variants other than p.Val50Met have also been identified worldwide.</p><p>The frequency of hereditary ATTR amyloidosis caused by the variant <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a> is estimated at 1:538 in northern Portugal (Povoa do Varzim and Vila do Conde), the largest cluster worldwide of individuals with hereditary ATTR amyloidosis.</p><p>In individuals of northern European origin in the US, the frequency of <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a>-related hereditary ATTR amyloidosis is estimated at 1:100,000 [<a class="bk_pop" href="#tfap.REF.benson.2001">Benson 2001</a>].</p><p>The frequency of <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a> heterozygotes is 1.5% in the northern part of Sweden [<a class="bk_pop" href="#tfap.REF.holmgren.1994.351">Holmgren et al 1994</a>]; however, the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> is very low in this area [<a class="bk_pop" href="#tfap.REF.hellman.2008.181">Hellman et al 2008</a>] (see <a href="#tfap.Penetrance">Penetrance</a>).</p><p>The frequency of <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val142Ile</a> in the African American population is 3.0%-3.9%; most <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> individuals develop late-onset cardiac amyloidosis. More than 5% of the population in some areas of West Africa is heterozygous for this variant. In the US, the frequency of p.Val142Ile in the white and Hispanic populations is 0.44% and 0.0%, respectively [<a class="bk_pop" href="#tfap.REF.jacobson.1997.466">Jacobson et al 1997</a>, <a class="bk_pop" href="#tfap.REF.yamashita.2005.127">Yamashita et al 2005</a>].</p></div></div><div id="tfap.Genetically_Related_Allelic_Disorde"><h2 id="_tfap_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p><b>Familial euthyroid hyperthyroxinemia</b> is caused by benign variants in <i>TTR</i>, including <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Gly26Ser</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Ala129Thr</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Ala129Val</a>, and <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Thr139Met</a> [<a class="bk_pop" href="#tfap.REF.nakazato.1998.528">Nakazato 1998</a>, <a class="bk_pop" href="#tfap.REF.benson.2001">Benson 2001</a>, <a class="bk_pop" href="#tfap.REF.saraiva.2001.493">Saraiva 2001</a>]. The TTR protein binds approximately 15% of serum thyroxine. These variants increase total serum thyroxine concentration because of their increased affinity for thyroxine; however, they increase neither free thyroxine nor free triiodothyronine. Therefore, individuals with these sequence variants develop no clinical symptoms (i.e., they are euthyroid).</p><p><b>Wild type ATTR amyloidosis</b> (previously called senile systemic amyloidosis, or senile cardiac amyloidosis) results from the pathologic deposition of wild type TTR, predominantly in the heart. Pathologic deposits are also seen in the lungs, blood vessels, and the renal medulla of the kidneys [<a class="bk_pop" href="#tfap.REF.westermark.2003.48">Westermark et al 2003</a>]. Wild type ATTR amyloidosis affects mainly the elderly but is rarely diagnosed during life [<a class="bk_pop" href="#tfap.REF.sekijima.2018.8">Sekijima et al 2018</a>]. Thus, the precise prevalence of wild type ATTR amyloidosis is still unknown, but the examination of autopsy samples revealed a prevalence of 10%-25% in the elderly (age &#x0003e;80 years) [<a class="bk_pop" href="#tfap.REF.cornwell.1988.648">Cornwell et al 1988</a>, <a class="bk_pop" href="#tfap.REF.ueda.2011.1533">Ueda et al 2011</a>].</p><p>Wild type ATTR amyloidosis typically does not cause symptoms or can result in cardiac symptoms. The majority of individuals with wild type ATTR amyloidosis present with carpal tunnel syndrome [<a class="bk_pop" href="#tfap.REF.nakagawa.2016.58">Nakagawa et al 2016</a>]. Wild type ATTR amyloidosis should be distinguished from hereditary ATTR amyloidosis with variant TTR or other forms of amyloidosis such as primary (AL) amyloidosis. In contrast to the rapid progression of heart failure in AL amyloidosis, wild type ATTR amyloidosis results in slowly progressive heart failure [<a class="bk_pop" href="#tfap.REF.ng.2005.1425">Ng et al 2005</a>]. <a class="bk_pop" href="#tfap.REF.westermark.2003.48">Westermark et al [2003]</a> have indicated that the lung may be a more reliable tissue for amyloid detection than the heart.</p></div><div id="tfap.Differential_Diagnosis"><h2 id="_tfap_Differential_Diagnosis_">Differential Diagnosis</h2><div id="tfap.T.other_amyloidoses_to_consider_in" class="table"><h3><span class="label">Table 3a. </span></h3><div class="caption"><p>Other Amyloidoses to Consider in the Differential Diagnosis of Hereditary Transthyretin (ATTR) Amyloidosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1194/table/tfap.T.other_amyloidoses_to_consider_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tfap.T.other_amyloidoses_to_consider_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_1" rowspan="2" colspan="2" scope="colgroup" headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Features of This Disorder</th></tr><tr><th headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_4" id="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping</th><th headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_4" id="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing</th></tr></thead><tbody><tr><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Neuropathic amyloidoses</td><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Apo AI (AAPoAI) amyloidosis (OMIM <a href="https://omim.org/entry/105200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">105200</a>)</td><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>APOA1</i></td><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_4 hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Nephropathy</div></li><li class="half_rhythm"><div>Peripheral neuropathy</div></li><li class="half_rhythm"><div>Cardiomyopathy</div></li></ul>
</td><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_4 hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Hepatomegaly</div></li><li class="half_rhythm"><div>Swelling of testis</div></li></ul>
</td></tr><tr><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gelsolin (AGel) amyloidosis (OMIM <a href="https://omim.org/entry/105120" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">105120</a>)</td><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GSN</i></td><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_4 hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Peripheral neuropathy</div></li><li class="half_rhythm"><div>Renal failure</div></li></ul>
</td><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_4 hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Cranial neuropathy</div></li><li class="half_rhythm"><div>Corneal lattice dystrophy</div></li><li class="half_rhythm"><div>Cutis laxa</div></li></ul>
</td></tr><tr><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Systemic amyloidoses</td><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Wild type transthyretin amyloidosis (senile systemic amyloidosis)</td><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_2 hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_3" rowspan="2" colspan="2" style="text-align:left;vertical-align:middle;">NA<br />(acquired disorders)</td><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_4 hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Cardiomyopathy</div></li><li class="half_rhythm"><div>Carpal tunnel syndrome</div></li><li class="half_rhythm"><div>Peripheral neuropathy (mild or absent)</div></li></ul>
</td><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_4 hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>No <i>TTR</i> pathogenic variants</div></li><li class="half_rhythm"><div>Severe peripheral neuropathy is rare</div></li></ul>
</td></tr><tr><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Immunoglobulin (AL) amyloidosis</td><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_4 hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_2_1" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Neuropathic symptoms incl polyneuropathy, autonomic neuropathy, &#x00026; carpal tunnel syndrome in ~1/3 of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals</div></li><li class="half_rhythm"><div>Cardiomyopathy</div></li><li class="half_rhythm"><div>Renal failure</div></li></ul>
</td><td headers="hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_1_4 hd_h_tfap.T.other_amyloidoses_to_consider_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>May be difficult to distinguish clinically</div></li><li class="half_rhythm"><div>Immunohisto-chemical study or mass spectrometry of biopsied tissue required for diagnosis</div></li><li class="half_rhythm"><div>Positive serum &#x00026;/or urine monoclonal protein</div></li><li class="half_rhythm"><div>Negative myocardial technetium-99m-pyrophosphate scintigraphy</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; NA = not applicable</p></div></dd><dt></dt><dd><div><p class="no_margin">A total of 35 amyloidogenic proteins including transthyretin (TTR) have been identified in human amyloidoses [<a class="bk_pop" href="#tfap.REF.sipe.2016.209">Sipe et al 2016</a>]. Among the hereditary amyloidoses, hereditary ATTR amyloidosis is the most prevalent. [<a class="bk_pop" href="#tfap.REF.benson.2001">Benson 2001</a>, <a class="bk_pop" href="#tfap.REF.hund.2001.431">Hund et al 2001</a>, <a class="bk_pop" href="#tfap.REF.benson.2005.75">Benson 2005</a>].</p></div></dd></dl></div></div></div><div id="tfap.T.nonamyloidotic_neuropathies_to_co" class="table"><h3><span class="label">Table 3b. </span></h3><div class="caption"><p>Non-Amyloidotic Neuropathies to Consider in the Differential Diagnosis of Hereditary Transthyretin (ATTR) Amyloidosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1194/table/tfap.T.nonamyloidotic_neuropathies_to_co/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tfap.T.nonamyloidotic_neuropathies_to_co_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_1" style="text-align:center;vertical-align:middle;">Disorder</th><th id="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Clinical Features of This Disorder</th></tr><tr><th headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_4" id="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping</th><th headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_4" id="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing</th></tr></thead><tbody><tr><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/cmt/">Charcot-Marie-Tooth hereditary neuropathy</a></td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Many&#x000a0;<sup>1</sup></td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD<br />AR<br />XL</td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_4 hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Present w/peripheral neuropathy</td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_4 hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>No cardiomyopathy</div></li><li class="half_rhythm"><div>Disease progression is slower than in hereditary ATTR amyloidosis.</div></li></ul>
</td></tr><tr><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/fabry/">Fabry disease</a></td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GLA</i></td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_4 hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Present w/cardiomyopathy, nephropathy, &#x00026; peripheral nephropathy</td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_4 hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Juvenile onset, esp in males</div></li><li class="half_rhythm"><div>Angiokeratoma</div></li><li class="half_rhythm"><div>&#x02193; &#x003b1; galactosidase activity</div></li></ul>
</td></tr><tr><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mitochondrial disorders incl MELAS (see <a href="/books/n/gene/mt-overview/">Mitochondrial Disorders Overview</a>)</td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Many&#x000a0;<sup>2</sup></td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mat<br />AR<br />AD</td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_4 hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Present w/cardiomyopathy</div></li><li class="half_rhythm"><div>Neuropathy &#x00026;/or nephropathy variably present</div></li></ul>
</td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_4 hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Myopathy</div></li><li class="half_rhythm"><div>Diabetes</div></li><li class="half_rhythm"><div>Deafness</div></li><li class="half_rhythm"><div>&#x02191; serum lactate &#x00026; pyruvate levels</div></li></ul>
</td></tr><tr><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/hyper-card/">Hereditary hypertrophic cardiomyopathy</a></td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Many&#x000a0;<sup>3</sup></td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_4 hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Present w/cardiomyopathy</td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_4 hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No peripheral/autonomic neuropathy</td></tr><tr><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cardiac sarcoidosis</td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_2 hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_3" rowspan="4" colspan="2" style="text-align:left;vertical-align:middle;">NA<br />(acquired disorders)</td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_4 hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Present w/cardiomyopathy</div></li><li class="half_rhythm"><div>Peripheral neuropathy &#x00026;/or nephropathy variably present</div></li></ul>
</td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_4 hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Negative family history</div></li><li class="half_rhythm"><div>Uveitis</div></li><li class="half_rhythm"><div>Hilar lymphadenopathy</div></li><li class="half_rhythm"><div>&#x02191; serum angiotensin-converting enzyme level</div></li></ul>
</td></tr><tr><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)</td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_4 hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_2_1" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">Present w/peripheral neuropathy</td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_4 hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Negative family history</div></li><li class="half_rhythm"><div>No cardiomyopathy</div></li><li class="half_rhythm"><div>Most common misdiagnosis in those w/ATTR amyloidosis&#x000a0;<sup>4</sup></div></li></ul>
</td></tr><tr><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Crow-Fukase syndrome (aka POEMS)</td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_4 hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_2_2" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Negative family history</div></li><li class="half_rhythm"><div>Positive serum &#x00026;/or urine monoclonal protein</div></li><li class="half_rhythm"><div>&#x02191; serum vascular endothelial growth factor level</div></li></ul>
</td></tr><tr><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Diabetic neuropathy</td><td headers="hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_1_4 hd_h_tfap.T.nonamyloidotic_neuropathies_to_co_1_1_2_2" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Negative family history</div></li><li class="half_rhythm"><div>&#x02191; blood sugar level</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">&#x02191; = high; &#x02193; = low; AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; Mat = maternal; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; POEMS = plasma cell neoplasia w/polyneuropathy, organomegaly, endocrinopathy, M protein, &#x00026; skin changes; NA = not applicable; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="tfap.TF.3b.1"><p class="no_margin">More than 80 different genes are associated with CMT [<a class="bk_pop" href="#tfap.REF.stojkovic.2016.775">Stojkovic 2016</a>].</p></div></dd><dt>2. </dt><dd><div id="tfap.TF.3b.2"><p class="no_margin">Pathogenic variants known to cause MELAS have been identified in mtDNA tRNA genes including <i>MT-TL-1</i>, <i>MT-ND5</i>, <i>MT-TC</i>, <i>MT-TK</i>, <i>MT-TV</i>, <i>MT-TF</i>, <i>MT-TQ</i>, <i>MT-TS1</i>, <i>MT-TS2</i>, and <i>MT-TW</i>, and in the protein-encoding genes <i>MT-CO1</i>, <i>MT-CO2</i>, <i>MT-CO3</i>, <i>MT-CYB</i>, <i>MT-ND1</i>, <i>MT-ND3</i>, and <i>MT-ND6</i>. Pathogenic variants in many other genes cause mitochondrial disorders (see <a href="/books/n/gene/mt-overview/">Mitochondrial Disorders Overview</a>).</p></div></dd><dt>3. </dt><dd><div id="tfap.TF.3b.3"><p class="no_margin">Pathogenic variants known to cause hereditary hypertrophic cardiomyopathy have been identified in <i>MYH7</i>, <i>MYBPC3</i>, <i>TNNT2</i>, <i>TNNI3</i>, <i>TPM1</i>, <i>MYL2</i>, <i>MYL3</i>, <i>ACTC1</i>, <i>CSRP3</i>, <i>ACTN2</i>, <i>MYH6</i>, <i>TCAP</i>, <i>TNNC1</i>, <i>PLN</i>, <i>MYOZ2</i>, and <i>NEXN</i> (see <a href="/books/n/gene/hyper-card/">Hypertrophic Cardiomyopathy Overview</a>).</p></div></dd><dt>4. </dt><dd><div id="tfap.TF.3b.4"><p class="no_margin">18/90 individuals with hereditary ATTR amyloidosis without a family history were mistakenly diagnosed with CIDP [<a class="bk_pop" href="#tfap.REF.plant_bordeneuve.2007.693">Plant&#x000e9;-Bordeneuve et al 2007</a>].</p></div></dd></dl></div></div></div></div><div id="tfap.Management"><h2 id="_tfap_Management_">Management</h2><div id="tfap.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with hereditary transthyretin (ATTR) amyloidosis, the evaluations summarized in <a class="figpopup" href="/books/NBK1194/table/tfap.T.recommended_evaluations_following/?report=objectonly" target="object" rid-figpopup="figtfapTrecommendedevaluationsfollowing" rid-ob="figobtfapTrecommendedevaluationsfollowing">Table 4</a> (if not performed as part of the evaluation that led to the diagnosis) are recommended.</p><div id="tfap.T.recommended_evaluations_following" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis in Individuals with Hereditary Transthyretin (ATTR) Amyloidosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1194/table/tfap.T.recommended_evaluations_following/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tfap.T.recommended_evaluations_following_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tfap.T.recommended_evaluations_following_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System</th><th id="hd_h_tfap.T.recommended_evaluations_following_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_tfap.T.recommended_evaluations_following_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Complete neurologic assessment incl baseline nerve conduction studies</td><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiac</b></td><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Echocardiogram</td><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To evaluate ventricular wall thickness, ventricular septal thickness, diastolic &#x00026; systolic function, &#x00026; longitudinal strain</td></tr><tr><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Electrocardiogram</td><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To evaluate for low voltage in the standard limb leads &#x00026; QS pattern in the right precordial leads w/ or w/out conduction blocks</td></tr><tr><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Myocardial technetium-99m-pyrophosphate scintigraphy</td><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To visualize amyloid deposition in heart</td></tr><tr><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>CNS</b></td><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Gadolinium-enhanced MRI of brain &#x00026; spinal cord</div></li><li class="half_rhythm"><div>Amyloid PET imaging using PiB</div></li></ul>
</td><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To evaluate CNS amyloidosis</td></tr><tr><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Ophthalmologic</b></td><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ophthalmologic evaluation</td><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluate for vitreous opacities &#x00026; glaucoma.</td></tr><tr><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Nephrologic</b></td><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Routine blood &#x00026; urine examinations for evaluation of renal function</td><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Other</b></td><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consultation w/clinical geneticist &#x00026;/or genetic counselor</td><td headers="hd_h_tfap.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">PiB = Pittsburgh compound B</p></div></dd></dl></div></div></div></div><div id="tfap.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><div id="tfap.T.treatment_of_manifestations_in_in" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with Hereditary Transthyretin (ATTR) Amyloidosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1194/table/tfap.T.treatment_of_manifestations_in_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tfap.T.treatment_of_manifestations_in_in_lrgtbl__"><table><thead><tr><th id="hd_h_tfap.T.treatment_of_manifestations_in_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation</th><th id="hd_h_tfap.T.treatment_of_manifestations_in_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th></tr></thead><tbody><tr><td headers="hd_h_tfap.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Peripheral &#x00026; autonomic neuropathy</td><td headers="hd_h_tfap.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Orthotopic liver transplantation</div></li><li class="half_rhythm"><div>TTR tetramer stabilizers</div></li><li class="half_rhythm"><div>Gene-silencing therapies</div></li></ul>
</td></tr><tr><td headers="hd_h_tfap.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cardiomyopathy</td><td headers="hd_h_tfap.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">TTR tetramer stabilizers</td></tr><tr><td headers="hd_h_tfap.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Carpal tunnel syndrome</td><td headers="hd_h_tfap.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Carpal tunnel release surgery</td></tr><tr><td headers="hd_h_tfap.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Vitreous involvement</td><td headers="hd_h_tfap.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Vitrectomy</td></tr><tr><td headers="hd_h_tfap.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Glaucoma</td><td headers="hd_h_tfap.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Glaucoma surgery</td></tr><tr><td headers="hd_h_tfap.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2nd- or 3rd-degree AV block &#x00026; sick sinus syndrome</td><td headers="hd_h_tfap.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cardiac pacemaker implantation</td></tr></tbody></table></div></div><p><b>Orthotopic liver transplantation (OLTX).</b> Orthotopic liver transplantation (OLTX) provides a wild type <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> expressing normal TTR in the liver, the main source of serum TTR protein. Successful OLTX results in rapid disappearance of variant TTR protein from the serum and thus halts the progression of peripheral and/or autonomic neuropathy. It has been shown by pre- and postoperative sural nerve biopsy that myelinated nerve fibers regenerate after OLTX [<a class="bk_pop" href="#tfap.REF.ikeda.1997.618">Ikeda et al 1997</a>].</p><p><b>Recommended clinical criteria for OLTX</b> in individuals with TTR amyloid polyneuropathy [<a class="bk_pop" href="#tfap.REF.takei.1999.592">Takei et al 1999</a>, <a class="bk_pop" href="#tfap.REF.adams.2000.1495">Adams et al 2000</a>] include the following:</p><ul><li class="half_rhythm"><div>Age younger than 60 years</div></li><li class="half_rhythm"><div>Disease duration less than five years</div></li><li class="half_rhythm"><div>Either polyneuropathy that is restricted to the lower extremities or autonomic neuropathy alone</div></li><li class="half_rhythm"><div>No significant cardiac or renal dysfunction</div></li></ul><p>As of the end of December 2017, 2,236 individuals with hereditary ATTR amyloidosis, approximately 90% of whom were <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a> variant, had undergone liver transplantation (<a href="http://www.fapwtr.org/ram_fap.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fapwtr.org/ram_fap.htm</a>) [<a class="bk_pop" href="#tfap.REF.ericzon.2000.145">Ericzon et al 2000</a>, <a class="bk_pop" href="#tfap.REF.ikeda.2003.547">Ikeda et al 2003</a>, <a class="bk_pop" href="#tfap.REF.herlenius.2004.64">Herlenius et al 2004</a>, <a class="bk_pop" href="#tfap.REF.stangou.2004.615">Stangou &#x00026; Hawkins 2004</a>]. The five-year survival rate was significantly higher in individuals with the p.Val50Met variant than in those with other pathogenic variants (80% vs 57%, p=0.001) [<a class="bk_pop" href="#tfap.REF.ericzon.2000.145">Ericzon et al 2000</a>, <a class="bk_pop" href="#tfap.REF.ikeda.2003.547">Ikeda et al 2003</a>]. The most common causes of postoperative death were cardiovascular events (29%) and septicemia (26%) [<a class="bk_pop" href="#tfap.REF.ikeda.2003.547">Ikeda et al 2003</a>].</p><p><b>Predictors of poor outcomes in transplanted individuals</b> include [<a class="bk_pop" href="#tfap.REF.adams.2000.1495">Adams et al 2000</a>, <a class="bk_pop" href="#tfap.REF.ikeda.2003.547">Ikeda et al 2003</a>, <a class="bk_pop" href="#tfap.REF.yamamoto.2007.2597">Yamamoto et al 2007</a>, <a class="bk_pop" href="#tfap.REF.algalarrondo.2015.2154">Algalarrondo et al 2015</a>, <a class="bk_pop" href="#tfap.REF.ericzon.2015.1847">Ericzon et al 2015</a>]:</p><ul><li class="half_rhythm"><div>Poor nutritional condition (modified body mass index &#x0003c;600)</div></li><li class="half_rhythm"><div>Severe polyneuropathy (Norris score &#x0003c;55/81)</div></li><li class="half_rhythm"><div>Permanent urinary incontinence</div></li><li class="half_rhythm"><div>Marked postural hypotension</div></li><li class="half_rhythm"><div>A fixed pulse rate</div></li><li class="half_rhythm"><div>Age &#x02265;50 years (especially in males)</div></li><li class="half_rhythm"><div>Pathogenic variants other than <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a></div></li><li class="half_rhythm"><div>Presence of cardiomyopathy</div></li></ul><p><b>OLTX is not effective</b> in the non-neuropathic forms of hereditary ATTR amyloidosis (i.e., cardiac amyloidosis, leptomeningeal amyloidosis, and <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> oculoleptomeningeal amyloidosis [FOLMA]).</p><p>Cardiomyopathy was reported to progress after OLTX in some individuals with specific pathogenic variants other than <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a> (e.g., <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Ala56Pro</a>, <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Glu62Gly</a>, and <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Ser97Tyr</a>) [<a class="bk_pop" href="#tfap.REF.dubrey.1997.74">Dubrey et al 1997</a>, <a class="bk_pop" href="#tfap.REF.stangou.1998.229">Stangou et al 1998</a>, <a class="bk_pop" href="#tfap.REF.yazaki.2000b.702">Yazaki et al 2000b</a>, <a class="bk_pop" href="#tfap.REF.h_rnsten.2004.112">H&#x000f6;rnsten et al 2004</a>]. It is presumed that amyloid cardiomyopathy may accelerate after OLTX by progressive deposition of wild type TTR on a template of amyloid derived from variant TTR [<a class="bk_pop" href="#tfap.REF.yazaki.2000b.702">Yazaki et al 2000b</a>, <a class="bk_pop" href="#tfap.REF.h_rnsten.2004.112">H&#x000f6;rnsten et al 2004</a>]. Therefore, it is critical to assess the severity of cardiac amyloidosis when considering OLTX [<a class="bk_pop" href="#tfap.REF.coutinho.2004.201">Coutinho et al 2004</a>, <a class="bk_pop" href="#tfap.REF.juneblad.2004.208">Juneblad et al 2004</a>].</p><p>Individuals with leptomeningeal involvement may not be candidates for liver transplantation because amyloidogenic TTR variants that cause intracranial amyloid deposits are considered to be derived from the choroid plexus. Leptomeningeal amyloidosis / cerebral amyloid angiopathy may develop after OLTX as the choroid plexus continues to produce variant TTR [<a class="bk_pop" href="#tfap.REF.maia.2015.159">Maia et al 2015</a>, <a class="bk_pop" href="#tfap.REF.sekijima.2016.773">Sekijima et al 2016</a>].</p><p>Amyloid ophthalmopathy (e.g., vitreous opacities and glaucoma) may also progress after OLTX, possibly as the result of <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> production of variant TTR in the retinal epithelium.</p><p>Note: Because liver involvement in hereditary ATTR amyloidosis is minimal, the liver of an individual with hereditary ATTR amyloidosis can be grafted into an individual with liver cancer or end-stage liver disease (so-called "domino" liver transplantation). Since 1995, 1,254 domino liver transplantations have been performed. Several individuals who received a liver graft from heterozygotes with hereditary ATTR amyloidosis developed symptomatic systemic ATTR amyloidosis [<a class="bk_pop" href="#tfap.REF.stangou.2005.2356">Stangou et al 2005</a>, <a class="bk_pop" href="#tfap.REF.goto.2006.2512">Goto et al 2006</a>, <a class="bk_pop" href="#tfap.REF.barreiros.2010.109">Barreiros et al 2010</a>, <a class="bk_pop" href="#tfap.REF.llad_.2010.1386">Llad&#x000f3; et al 2010</a>, <a class="bk_pop" href="#tfap.REF.adams.2011.174">Adams et al 2011</a>, <a class="bk_pop" href="#tfap.REF.obayashi.2011.449">Obayashi et al 2011</a>].</p><p><b>TTR tetramer stabilizers (tafamidis, diflunisal).</b> Another therapeutic option for ameliorating hereditary ATTR amyloidosis is to stabilize the native TTR tetramer structure, as tetramer dissociation is necessary for ATTR amyloid fibril formation. To date, clinical effect of two TTR tetramer stabilizers, tafamidis and diflunisal, has been confirmed:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Tafamidis.</b> In a Phase II/III study, tafamidis (Vyndaqel<sup>&#x000ae;</sup>) showed efficacy in delaying peripheral neurologic impairment compared with individuals treated with placebo. In addition, tafamidis resulted in improved nutritional status (modified body mass index) of the study participants [<a class="bk_pop" href="#tfap.REF.coelho.2012.785">Coelho et al 2012</a>].</div><div class="half_rhythm">Based on these findings, tafamidis was approved for hereditary ATTR amyloidosis treatment in more than 40 countries.</div><div class="half_rhythm">Among individuals with early-onset disease (age &#x0003c;50 years), tafamidis reduced the mortality risk over that of untreated individuals by 91%, and that of OLTX-treated individuals by 63%. Among individuals with late-onset disease (&#x02265;50 years), tafamidis reduced mortality risk over that of untreated individuals by 82% [<a class="bk_pop" href="#tfap.REF.coelho.2018.e1999">Coelho et al 2018</a>].</div><div class="half_rhythm">In a Phase III clinical trial for ATTR cardiomyopathy including hereditary and wild type ATTR amyloidosis, tafamidis reduced mortality of all causes and cardiovascular-related hospitalizations, and reduced the decline in functional capacity and quality of life as compared with placebo [<a class="bk_pop" href="#tfap.REF.maurer.2018.1007">Maurer et al 2018</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Diflunisal.</b> Phase III studies of diflunisal showed efficacy in delaying peripheral neurologic impairment compared with individuals treated with placebo [<a class="bk_pop" href="#tfap.REF.berk.2013.2658">Berk et al 2013</a>].</div></li></ul><p><b>Gene-silencing therapies (patisiran, inotersen).</b> Gene-silencing approaches using antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) are promising therapeutic strategies for amelioration of hereditary ATTR amyloidosis, as reduction of amyloid fibril precursor protein level has proven to be effective in AL amyloidosis (chemotherapy to reduce amyloidogenic immunoglobulin light chain) and amyloid A protein (AA) amyloidosis (biologic agents and immunosuppressive agents to reduce serum amyloid A protein) [<a class="bk_pop" href="#tfap.REF.sekijima.2015.1036">Sekijima 2015</a>].</p><p><b>Patisiran.</b> In a Phase III clinical trial, patisiran (Onpattro&#x02122;), a siRNA therapeutic agent, showed efficacy in halting peripheral neurologic impairment compared with placebo [<a class="bk_pop" href="#tfap.REF.adams.2018.11">Adams et al 2018</a>]. Patisiran will be approved by 2019 for treatment of hereditary ATTR amyloidosis in several countries in North and South America, Europe, and Asia.</p><p><b>Inotersen.</b> In a Phase III clinical trial, inotersen (Tegsedi&#x02122;), an ASO therapeutic agent, showed efficacy in delaying peripheral neurologic impairment compared with placebo [<a class="bk_pop" href="#tfap.REF.benson.2018.22">Benson et al 2018</a>]. Inotersen is under regulatory review for marketing authorization in the US and EU.</p></div><div id="tfap.Surveillance"><h3>Surveillance</h3><p>Serial nerve conduction studies can be used to objectively monitor the course of the polyneuropathy.</p><p>Serial electrocardiogram, echocardiography, and serum B-type natriuretic peptide levels can be used to monitor the course of cardiomyopathy and conduction block.</p><p>Modified body mass index can be used to monitor nutritional status.</p></div><div id="tfap.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Since most individuals with hereditary ATTR amyloidosis have decreased temperature and pain perception, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals should not use local heating appliances, such as hot-water bottles, which can cause low-temperature burn injury.</p></div><div id="tfap.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the status of apparently asymptomatic older and younger at-risk relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual so that morbidity and mortality can be reduced by early diagnosis and treatment.</p><p>Evaluations can include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the <i>TTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known;</div></li><li class="half_rhythm"><div>Clinical diagnostic evaluations if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is not known.</div></li></ul><p>See <a href="#tfap.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="tfap.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Strategies of potential molecular therapies for hereditary ATTR amyloidosis include the following:</p><ul><li class="half_rhythm"><div><b>Inhibition of synthesis of variant TTR.</b> A Phase II clinical trial of a new siRNA therapeutic, ALN-TTRsc, is under way.</div></li><li class="half_rhythm"><div><b>Stabilization of variant TTR.</b> A Phase II clinical trial of a new TTR tetramer stabilizer, AG10, is under way.</div></li><li class="half_rhythm"><div><b>Disruption of insoluble amyloid fibrils</b></div><ul><li class="half_rhythm"><div>A Phase III study of combination therapy with doxycycline, an antibiotic that disrupts TTR amyloid fibrils, and tauroursodeoxycholic acid (TUDCA), a biliary acid that reduces non-fibrillar TTR aggregates, is under way.</div></li><li class="half_rhythm"><div>A Phase II clinical trial of combination therapy of miridesap (a small molecule that depletes circulating serum amyloid P component, SAP) followed by dezamizumab (anti-SAP antibody) is under way.</div></li><li class="half_rhythm"><div>A Phase I clinical trial of PRX004, an investigational antibody designed to target and clear the pathogenic, misfolded forms of the TTR protein found in ATTR amyloidosis without affecting the native, or normal, tetrameric form of the protein, is under way.</div></li></ul></li></ul><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="tfap.Genetic_Counseling"><h2 id="_tfap_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="tfap.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Hereditary transthyretin (ATTR) amyloidosis is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="tfap.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm">Some individuals diagnosed with hereditary ATTR amyloidosis have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div><div class="half_rhythm">If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>TTR</i> pathogenic variants (reported in at least 26 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals), both parents may be affected and/or <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>TTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div class="half_rhythm">A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with hereditary ATTR amyloidosis may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of cases caused by a <i>de novo</i> pathogenic variant is unknown.</div></li><li class="half_rhythm"><div class="half_rhythm">Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the pathogenic variant in <i>TTR</i> has been identified in the proband.</div></li><li class="half_rhythm"><div class="half_rhythm">If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. Though theoretically possible, no instances of germline mosaicism have been reported.</div></li><li class="half_rhythm"><div class="half_rhythm">The family history of some individuals diagnosed with hereditary ATTR amyloidosis may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate clinical evaluation and/or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the genetic status of the parents:</p><ul><li class="half_rhythm"><div>If one parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or known to have a <i>TTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to sibs is 50%.</div></li><li class="half_rhythm"><div>If both parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or known to have a <i>TTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, sibs of the proband have a 50% chance of inheriting one <i>TTR</i> pathogenic variant and a 25% chance of inheriting two <i>TTR</i> pathogenic variants.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a known <i>TTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that cannot be detected in the leukocyte DNA of either parent, the <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to sibs is estimated to be 1% because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#tfap.REF.rahbari.2016.126">Rahbari et al 2016</a>].</div></li><li class="half_rhythm"><div>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with clinically unaffected parents are presumed to be at increased risk for hereditary ATTR amyloidosis because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent or the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Each child of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> who is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>TTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has a 50% risk of inheriting the <i>TTR</i> pathogenic variant.</div></li><li class="half_rhythm"><div>All offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> who is <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for a <i>TTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> will inherit the variant.</div></li></ul><p><b>Other family members.</b> The risk to other family members depends on the genetic status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members are at risk.</p></div><div id="tfap.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#tfap.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Predictive testing (i.e., testing of asymptomatic at-risk individuals)</b></p><ul><li class="half_rhythm"><div>Predictive testing for at-risk relatives is possible once the <i>TTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member. Such testing is not useful in predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals.</div></li><li class="half_rhythm"><div>Potential consequences of such testing (including, but not limited to, socioeconomic changes and the need for long-term follow up and evaluation arrangements for individuals with a positive test result) as well as the capabilities and limitations of predictive testing should be discussed in the context of formal <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> prior to testing.</div></li></ul><p><b>Predictive testing in minors (i.e., testing of asymptomatic at-risk individuals younger than age 18 years)</b></p><ul><li class="half_rhythm"><div>For asymptomatic minors at risk for adult-onset conditions for which early treatment would have no beneficial effect on disease morbidity and mortality, predictive genetic testing is considered inappropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.</div></li><li class="half_rhythm"><div>For more information, see the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</div></li></ul><p>In a family with an established diagnosis of hereditary ATTR amyloidosis, it is appropriate to consider testing of symptomatic individuals regardless of age.</p><p><b>Related liver transplantation donors.</b> In Japan, where liver transplantation from living, related donors is the generally accepted therapy for hereditary ATTR amyloidosis, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of asymptomatic adult relatives is always performed on family members volunteering to be donors.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals</p></div><div id="tfap.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>TTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for hereditary ATTR amyloidosis are possible.</p><p>Differences in perspective may exist among medical professionals and in families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="tfap.Resources"><h2 id="_tfap_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Amyloidosis Foundation (AF)</b></div><div>7151 North Main Street</div><div>Suite 2</div><div>Clarkston MI 48346</div><div><b>Email:</b> info@amyloidosis.org</div><div><a href="http://www.amyloidosisresearchfoundation.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.amyloidosisresearchfoundation.org</a></div></li><li class="half_rhythm"><div><b>American Liver Foundation</b></div><div>75 Maiden Lane</div><div>Suite 603</div><div>New York NY 10038</div><div><b>Phone:</b> 800-465-4837 (Toll-free HelpLine); 212-668-1000</div><div><b>Fax:</b> 212-483-8179</div><div><b>Email:</b> info@liverfoundation.org</div><div><a href="http://www.liverfoundation.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.liverfoundation.org</a></div></li><li class="half_rhythm"><div><b>Transthyretin Amyloidosis Outcomes Survey (THAOS)</b></div><div><b>Phone:</b> 617-252-5500</div><div><b>Fax:</b> 617-252-5501</div><div><b>Email:</b> THAOS@foldrx.com</div><div><a href="http://www.thaos.net" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Transthyretin Amyloidosis Outcomes Survey</a></div></li></ul></div><div id="tfap.Molecular_Genetics"><h2 id="_tfap_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="tfap.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Hereditary Transthyretin Amyloidosis: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1194/table/tfap.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tfap.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_tfap.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_tfap.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_tfap.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_tfap.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_tfap.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_tfap.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_tfap.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/7276" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>TTR</i></a></td><td headers="hd_b_tfap.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=7276" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">18q12<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_tfap.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P02766" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Transthyretin</a></td><td headers="hd_b_tfap.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://databases.lovd.nl/shared/genes/TTR" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TTR (transthyretin) gene homepage</a></td><td headers="hd_b_tfap.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=TTR" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TTR</a></td><td headers="hd_b_tfap.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=TTR[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TTR</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="tfap.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="tfap.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Hereditary Transthyretin Amyloidosis (<a href="/omim/105210,176300" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1194/table/tfap.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tfap.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/105210" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">105210</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/176300" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">176300</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TRANSTHYRETIN; TTR</td></tr></tbody></table></div></div><div id="tfap.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p>The main component of amyloid is protein fibrils. In hereditary transthyretin (ATTR) amyloidosis, the fibrils are mainly composed of self-aggregated TTR protein. TTR protein is potentially amyloidogenic because of its extensive beta-sheet structure. The key factor in amyloidogenesis in hereditary ATTR amyloidosis is the stability of the TTR protein [<a class="bk_pop" href="#tfap.REF.kelly.1998.101">Kelly 1998</a>, <a class="bk_pop" href="#tfap.REF.rochet.2000.60">Rochet &#x00026; Lansbury 2000</a>, <a class="bk_pop" href="#tfap.REF.sekijima.2005.73">Sekijima et al 2005</a>]. The TTR protein normally circulates in plasma as a soluble protein having a tetrameric structure. The amyloidogenic process occurs in two steps:</p><dl class="temp-labeled-list"><dt>1.</dt><dd><p class="no_top_margin">Soluble TTR tetramers dissociate into pro-amyloidogenic monomers that in turn polymerize into amyloid fibrils in certain tissues [<a class="bk_pop" href="#tfap.REF.kelly.1998.101">Kelly 1998</a>, <a class="bk_pop" href="#tfap.REF.rochet.2000.60">Rochet &#x00026; Lansbury 2000</a>].</p></dd><dt>2.</dt><dd><p class="no_top_margin">Pathogenic variants in <i>TTR</i> cause significant conformational change in TTR protein molecules, in turn disrupting the stability of the TTR tetramer. Tetramers containing variant TTR monomers more easily dissociate into pro-amyloidogenic monomers than do normal TTR tetramers [<a class="bk_pop" href="#tfap.REF.sekijima.2005.73">Sekijima et al 2005</a>].</p></dd></dl><p>It has been demonstrated that all disease-associated TTR variants are energetically (thermodynamically and kinetically) less stable than wild type TTR.</p><p><b>Gene structure.</b> Human <i>TTR</i> contains four exons and spans approximately 7 kb. All exons but <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1 consist of fewer than 200 base pairs. Exon 1 encodes a signal peptide and the first three amino acids of the mature protein. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1194/#tfap.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Nearly 150 <i>TTR</i> single-nucleotide variants and one <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> microdeletion have been identified in individuals with hereditary ATTR amyloidosis [<a class="bk_pop" href="#tfap.REF.connors.2000.54">Connors et al 2000</a>, <a class="bk_pop" href="#tfap.REF.benson.2001">Benson 2001</a>, <a class="bk_pop" href="#tfap.REF.saraiva.2001.493">Saraiva 2001</a>, <a class="bk_pop" href="#tfap.REF.connors.2003.160">Connors et al 2003</a>, <a class="bk_pop" href="#tfap.REF.benson.2007.411">Benson &#x00026; Kincaid 2007</a>]. No <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been described in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1, which encodes amino acids 1 through 3.</p><p>The <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val50Met</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, found worldwide, is the most widely studied <i>TTR</i> variant and is responsible for the well-known large foci of individuals with TTR amyloid polyneuropathy in Portugal, Sweden, and Japan. Several haplotypes are associated with p.Val50Met in different ethnic groups, suggesting that multiple founders spontaneously occurred in each group.</p><p>The <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Val142Ile</a> variant, present in 3.0%-3.9% of African Americans and more than 5.0% of the population in some areas of West Africa, is the most common amyloid-associated <i>TTR</i> variant worldwide [<a class="bk_pop" href="#tfap.REF.jacobson.1997.466">Jacobson et al 1997</a>, <a class="bk_pop" href="#tfap.REF.yamashita.2005.127">Yamashita et al 2005</a>].</p><p>Of note, suppressor variant <a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Thr139Met</a> is more stable than wild type TTR (e.g., individuals who were <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for p.Thr139Met and another <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> showed milder clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>).</p><div id="tfap.T.ttr_variants_discussed_in_this_ge" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p><i>TTR</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tfap.T.ttr_variants_discussed_in_this_ge_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change (Standard Nomenclature)&#x000a0;<sup>1,&#x000a0;2</sup></th><th id="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Standard Nomenclature)&#x000a0;<sup>1,&#x000a0;2</sup></th><th id="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype</th></tr></thead><tbody><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.76G&#x0003e;A</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly26Ser&#x000a0;<sup>3</sup></td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Benign</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.95T&#x0003e;C</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu32Pro</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LM, liver</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.113A&#x0003e;G</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp38Gly</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LM</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.112G&#x0003e;A</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp38Asn</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.118G&#x0003e;A</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val40Ile</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.130C&#x0003e;T</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro44Ser</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart, CTS, PN</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.133G&#x0003e;A</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala45Thr</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LM, PN</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.148G&#x0003e;A</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val50Met</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PN, AN, eye, LM</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.149T&#x0003e;G</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val50Gly</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LM, eye</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.166G&#x0003e;C</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala56Pro</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Eye, CTS</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.173A&#x0003e;C</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp58Ala</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PN, heart, lung</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.182G&#x0003e;T</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp61Leu</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Eye, PN</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.185A&#x0003e;G</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu62Gly</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PN, AN, heart</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.193G&#x0003e;A</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala65Thr</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.193G&#x0003e;T</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala65Ser</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.218G&#x0003e;A</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly73Glu</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LM, heart</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.218G&#x0003e;C</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly73Ala</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LM, PN, kidney, eye, heart</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.224T&#x0003e;C</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu75Pro</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart, AN, eye</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.227A&#x0003e;G</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His76Arg</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.229G&#x0003e;A</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly77Arg</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.233T&#x0003e;G</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu78His</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CTS, heart</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.250T&#x0003e;C</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe84Leu</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PN, CTS, heart</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.251T&#x0003e;C</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe84Ser</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LM, PN, eye</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.262A&#x0003e;T</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile88Leu</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart, PN</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.265T&#x0003e;C</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr89His</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Eye, LM</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.270A&#x0003e;C</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Lys90Asn</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Eye, CTS, PN</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.290C&#x0003e;A</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser97Tyr</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart, kidney, PN</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.301G&#x0003e;A</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala101Thr</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.302C&#x0003e;T</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala101Val</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.311T&#x0003e;G</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile104Ser</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart, CTS, eye</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.323A&#x0003e;G</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His108Arg</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.334G&#x0003e;A</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu112Lys</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.367C&#x0003e;A</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg123Ser</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.379A&#x0003e;G</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile127Val</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CTS, heart, PN</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.385G&#x0003e;A</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala129Thr&#x000a0;<sup>3</sup></td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Benign</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.386C&#x0003e;T</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala129Val&#x000a0;<sup>3</sup></td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Benign</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.386C&#x0003e;T</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala129Ser</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PN, AN</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.391C&#x0003e;A</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu131Met</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.401A&#x0003e;G</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr134Cys</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PN, AN, eye, LM</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.400T&#x0003e;C</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr134His</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CTS, skin</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.416C&#x0003e;T</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr139Met</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Non-amyloid, FEH</td></tr><tr><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.424G&#x0003e;A</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val142Ile</td><td headers="hd_h_tfap.T.ttr_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AN = autonomic neuropathy; CTS = carpal tunnel syndrome; FEH = <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> euthyroid hypertyroxinemia (see <a href="#tfap.Clinical_Characteristics">Genetically Related Disorders</a>); LM = leptomeningeal; PN = peripheral neuropathy</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="tfap.TF.6.1"><p class="no_margin">The nucleotide naming conventions follow those of Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). For the DNA nucleotide change the numbering begins at the Met initiation codon.</p></div></dd><dt>2. </dt><dd><div id="tfap.TF.6.2"><p class="no_margin">Note: Historic protein numbering was based on the mature protein after cleavage of a 20-amino-acid signal sequence (e.g., p.Leu32Pro was historically referred to as Leu12Pro). Standard nomenclature uses numbering beginning at the Met initiation codon. Variants reported in older literature may use historic nomenclature.</p></div></dd><dt>3. </dt><dd><div id="tfap.TF.6.3"><p class="no_margin">Causes <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> euthyroid hyperthyroxinemia; see <a href="#tfap.Genetically_Related_Allelic_Disorde">Genetically Related Disorders</a>.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The human <i>TTR</i> <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> encodes a 20-amino-acid signal peptide plus a 127-amino-acid mature protein with molecular mass 14 kd. TTR is a normal plasma protein synthesized predominantly by the liver. TTR is secreted into plasma as a tetrameric form (Mw = 55 kd) composed of four identical monomers; its plasma half-life is approximately one to two days. TTR concentration in plasma normally ranges from 20 to 40 mg/dL.</p><p>TTR transports thyroxine and retinol-binding protein (RBP) coupled to vitamin A. TTR binds virtually all of serum RBP and approximately 15% of serum thyroxine. In the cerebrospinal fluid, TTR is required for transport of serum thyroxine across the blood-brain barrier.</p><p>The choroid plexus is the source of the cerebrospinal fluid TTR. The TTR concentration in cerebrospinal fluid ranges from 10 &#x000b5;g/mL to 40 &#x000b5;g/mL.</p><p>TTR is also synthesized in the retina.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Amyloidogenic TTR variants reduce the stability of the physiologic TTR tetramer, and consequently produce a pro-amyloidogenic monomer more easily than normal TTR (see <a href="#tfap.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</a>) [<a class="bk_pop" href="#tfap.REF.kelly.1998.101">Kelly 1998</a>, <a class="bk_pop" href="#tfap.REF.rochet.2000.60">Rochet &#x00026; Lansbury 2000</a>, <a class="bk_pop" href="#tfap.REF.saraiva.2002.1">Saraiva 2002</a>, <a class="bk_pop" href="#tfap.REF.sekijima.2005.73">Sekijima et al 2005</a>].</p><p>In vitro amyloidogenicity correlates very well with protein stability. However, extremely destabilized (highly amyloidogenic in vitro) TTR variants do not induce severe systemic amyloidosis because serum concentrations of these TTR variants are very low due to protein degradation before secretion. The most clinically severe TTR variant (<a class="figpopup" href="/books/NBK1194/table/tfap.T.ttr_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figtfapTttrvariantsdiscussedinthisge" rid-ob="figobtfapTttrvariantsdiscussedinthisge">p.Leu75Pro</a>) exhibiting the earliest disease onset is the most destabilized variant that can be secreted at levels comparable to the wild type, consistent with disease-associated variants being <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> rather than <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> or <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a>. TTR variants that predominantly induce CNS amyloidosis are the least stable variants. The choroid plexus secretes highly destabilized TTR variants more efficiently than hepatic cells, thus, it is thought, accounting for CNS selective amyloid deposition (leptomeningeal amyloidosis) [<a class="bk_pop" href="#tfap.REF.hammarstr_m.2003.6656">Hammarstr&#x000f6;m et al 2003</a>, <a class="bk_pop" href="#tfap.REF.sekijima.2003.409">Sekijima et al 2003</a>, <a class="bk_pop" href="#tfap.REF.mitsuhashi.2005.216">Mitsuhashi et al 2005</a>, <a class="bk_pop" href="#tfap.REF.sekijima.2005.73">Sekijima et al 2005</a>].</p></div></div><div id="tfap.References"><h2 id="_tfap_References_">References</h2><div id="tfap.Published_Guidelines__Consensus_Sta"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="tfap.REF1">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 12-13-18. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF2">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset conditions. Available <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2018. Accessed 12-13-18.</div></li></ul></div><div id="tfap.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.adams.2018.11">Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plant&#x000e9;-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. <span><span class="ref-journal">N Engl J Med. </span>2018;<span class="ref-vol">379</span>:11–21.</span> [<a href="/pubmed/29972753" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29972753</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.adams.2011.174">Adams D, Lacroix C, Antonini T, Lozeron P, Denier C, Kreib AM, Epelbaum S, Blandin F, Karam V, Azoulay D, Adam R, Castaing D, Samuel D. Symptomatic and proven de novo amyloid polyneuropathy in familial amyloid polyneuropathy domino liver recipients. <span><span class="ref-journal">Amyloid. </span>2011;<span class="ref-vol">18</span> Suppl 1:174–7.</span> [<a href="/pubmed/21838477" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21838477</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.adams.2000.1495">Adams D, Samuel D, Goulon-Goeau C, Nakazato M, Costa PM, Feray C, Plante V, Ducot B, Ichai P, Lacroix C, Metral S, Bismuth H, Said G. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. <span><span class="ref-journal">Brain. </span>2000;<span class="ref-vol">123</span>:1495–504.</span> [<a href="/pubmed/10869060" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10869060</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.algalarrondo.2015.2154">Algalarrondo V, Antonini T, Th&#x000e9;audin M, Ducot B, Lozeron P, Chemla D, et al.  Prediction of long-term survival after liver transplantation for familial transthyretin amyloidosis. <span><span class="ref-journal">J Am Coll Cardiol. </span>2015;<span class="ref-vol">66</span>:2154–6.</span> [<a href="/pubmed/26541929" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26541929</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.ando.1997.295">Ando E, Ando Y, Okamura R, Uchino M, Ando M, Negi A. Ocular manifestations of familial amyloidotic polyneuropathy type I: long-term follow up. <span><span class="ref-journal">Br J Ophthalmol. </span>1997;<span class="ref-vol">81</span>:295–8.</span> [<a href="/pmc/articles/PMC1722164/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1722164</span></a>] [<a href="/pubmed/9215058" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9215058</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.ando.2005.1057">Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. <span><span class="ref-journal">Arch Neurol. </span>2005;<span class="ref-vol">62</span>:1057–62.</span> [<a href="/pubmed/16009758" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16009758</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.askanas.2000.544">Askanas V, Engel WK, Alvarez RB, Frangione B, Ghiso J, Vidal R. Inclusion body myositis, muscle blood vessel and cardiac amyloidosis, and transthyretin Val122Ile allele. <span><span class="ref-journal">Ann Neurol. </span>2000;<span class="ref-vol">47</span>:544–9.</span> [<a href="/pubmed/10762172" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10762172</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.barreiros.2010.109">Barreiros AP, Geber C, Birklein F, Galle PR, Otto G. Clinical symptomatic de novo systemic transthyretin amyloidosis 9 years after domino liver transplantation. <span><span class="ref-journal">Liver Transpl. </span>2010;<span class="ref-vol">16</span>:109.</span> [<a href="/pubmed/20035516" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20035516</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.beir_o.2004.2004">Beir&#x000e3;o I, Lobato L, Costa PM, Fonseca I, Mendes P, Silva M, Bravo F, Cabrita A, Porto G. Kidney and anemia in familial amyloidosis type I. <span><span class="ref-journal">Kidney Int. </span>2004;<span class="ref-vol">66</span>:2004–9.</span> [<a href="/pubmed/15496172" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15496172</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.benson.2001">Benson MD. Amyloidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. <em>The Metabolic and Molecular Bases of Inherited Diseases.</em> 8 ed. Vol 4. New York, NY: McGraw-Hill; 2001:5345-78.</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.benson.2005.75">Benson MD. Ostertag revisited: the inherited systemic amyloidoses without neuropathy. <span><span class="ref-journal">Amyloid. </span>2005;<span class="ref-vol">12</span>:75–87.</span> [<a href="/pubmed/16011983" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16011983</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.benson.2007.411">Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. <span><span class="ref-journal">Muscle Nerve. </span>2007;<span class="ref-vol">36</span>:411–23.</span> [<a href="/pubmed/17554795" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17554795</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.benson.2018.22">Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plant&#x000e9;-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Concei&#x000e7;&#x000e3;o I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T. Inotersen treatment for patients with hereditary transthyretin amyloidosis. <span><span class="ref-journal">N Engl J Med. </span>2018;<span class="ref-vol">379</span>:22–31.</span> [<a href="/pubmed/29972757" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29972757</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.berk.2013.2658">Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S, Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck PJ, et al.  Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. <span><span class="ref-journal">JAMA. </span>2013;<span class="ref-vol">310</span>:2658–67.</span> [<a href="/pmc/articles/PMC4139164/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4139164</span></a>] [<a href="/pubmed/24368466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24368466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.blevins.2003.1625">Blevins G, Macaulay R, Harder S, Fladeland D, Yamashita T, Yazaki M, Hamidi Asl K, Benson MD, Donat JR. Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. <span><span class="ref-journal">Neurology. </span>2003;<span class="ref-vol">60</span>:1625–30.</span> [<a href="/pubmed/12771253" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12771253</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.brett.1999.183">Brett M, Persey MR, Reilly MM, Revesz T, Booth DR, Booth SE, Hawkins PN, Pepys MB, Morgan-Hughes JA. Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. <span><span class="ref-journal">Brain. </span>1999;<span class="ref-vol">122</span>:183–90.</span> [<a href="/pubmed/10071047" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10071047</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.coelho.2018.e1999">Coelho T, In&#x000ea;s M, Concei&#x000e7;&#x000e3;o I, Soares M, de Carvalho M, Costa J. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. <span><span class="ref-journal">Neurology. </span>2018;<span class="ref-vol">91</span>:e1999–e2009.</span> [<a href="/pubmed/30333157" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30333157</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.coelho.2012.785">Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plant&#x000e9;-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Concei&#x000e7;&#x000e3;o IM, Schmidt HH, Trigo P, Kelly JW, Labaudini&#x000e8;re R, Chan J, Packman J, Wilson A, Grogan DR. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. <span><span class="ref-journal">Neurology. </span>2012;<span class="ref-vol">79</span>:785–792.</span> [<a href="/pmc/articles/PMC4098875/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4098875</span></a>] [<a href="/pubmed/22843282" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22843282</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.connors.2003.160">Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants. <span><span class="ref-journal">Amyloid. </span>2003;<span class="ref-vol">10</span>:160–84.</span> [<a href="/pubmed/14640030" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14640030</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.connors.2000.54">Connors LH, Richardson AM, Theberge R, Costello CE. Tabulation of transthyretin (TTR) variants as of 1/1/2000. <span><span class="ref-journal">Amyloid. </span>2000;<span class="ref-vol">7</span>:54–69.</span> [<a href="/pubmed/10842707" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10842707</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.cornwell.1988.648">Cornwell GG 3rd, Sletten K, Johansson B, Westermark P. Evidence that the amyloid fibril protein in senile systemic amyloidosis is derived from normal prealbumin. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>1988;<span class="ref-vol">154</span>:648–653.</span> [<a href="/pubmed/3135807" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3135807</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.coutinho.2004.201">Coutinho CA, Conceicao I, Almeida A, Cantinho G, Sargento L, Vagueiro MC. Early detection of sympathetic myocardial denervation in patients with familial amyloid polyneuropathy type I. <span><span class="ref-journal">Rev Port Cardiol. </span>2004;<span class="ref-vol">23</span>:201–11.</span> [<a href="/pubmed/15116456" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15116456</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.dubrey.1997.74">Dubrey SW, Davidoff R, Skinner M, Bergethon P, Lewis D, Falk RH. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. <span><span class="ref-journal">Transplantation. </span>1997;<span class="ref-vol">64</span>:74–80.</span> [<a href="/pubmed/9233704" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9233704</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.ellie.2001.135">Ellie E, Camou F, Vital A, Rummens C, Grateau G, Delpech M, Valleix S. Recurrent subarachnoid hemorrhage associated with a new transthyretin variant (Gly53Glu). <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">57</span>:135–7.</span> [<a href="/pubmed/11445644" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11445644</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.ericzon.2000.145">Ericzon BG, Holmgren G, Lundgren E, Suhr OB. New structural information and update on liver transplantation in transthyretin-associated amyloidosis. Report from the 4th International Symposium on Familial Amyloidotic Polyneuropathy and Other Transthyretin Related Disorders and the 3rd International Workshop on Liver Transplantation in Familial Amyloid Polyneuropathy, Ume&#x000e5; Sweden, June 1999. <span><span class="ref-journal">Amyloid. </span>2000;<span class="ref-vol">7</span>:145–7.</span> [<a href="/pubmed/10842720" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10842720</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.ericzon.2015.1847">Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, Furtado E, Barroso E, Daniel J, Samuel D, Adam R, Karam V, Poterucha J, Lewis D, Ferraz-Neto BH, Cruz MW, Munar-Ques M, Fabregat J, Ikeda S, Ando Y, Heaton N, Otto G, Suhr O. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? <span><span class="ref-journal">Transplantation. </span>2015;<span class="ref-vol">99</span>:1847–54.</span> [<a href="/pubmed/26308415" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26308415</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.ferlini.1996.10">Ferlini A, Salvi F, Uncini A, el-Chami J, Winter P, Altland K, Repetto M, Littardi M, Campoleoni A, Vezzoni P, Patrosso MC. Homozygosity and heterozygosity for the transthyretin Leu64 mutation: clinical, biochemical and molecular findings. <span><span class="ref-journal">Clin Genet. </span>1996;<span class="ref-vol">49</span>:10–4.</span> [<a href="/pubmed/8721565" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8721565</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.goto.2006.2512">Goto T, Yamashita T, Ueda M, Ohshima S, Yoneyama K, Nakamura M, Nanjo H, Asonuma K, Inomata Y, Watanabe S, Uchino M, Tanaka K, Ando Y. Iatrogenic amyloid neuropathy in a Japanese patient after sequential liver transplantation. <span><span class="ref-journal">Am J Transplant. </span>2006;<span class="ref-vol">6</span>:2512–5.</span> [<a href="/pubmed/16889603" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16889603</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.haagsma.2004.44">Haagsma EB, Hawkins PN, Benson MD, Lachmann HJ, Bybee A, Hazenberg BP. Familial amyloidotic polyneuropathy with severe renal involvement in association with transthyretin Gly47Glu in Dutch, British and American-Finnish families. <span><span class="ref-journal">Amyloid. </span>2004;<span class="ref-vol">11</span>:44–9.</span> [<a href="/pubmed/15185498" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15185498</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.hammarstr_m.2001.2459">Hammarstr&#x000f6;m P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. <span><span class="ref-journal">Science. </span>2001;<span class="ref-vol">293</span>:2459–62.</span> [<a href="/pubmed/11577236" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11577236</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.hammarstr_m.2003.6656">Hammarstr&#x000f6;m P, Sekijima Y, White JT, Wiseman RL, Lim A, Costello CE, Altland K, Garzuly F, Budka H, Kelly JW. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? <span><span class="ref-journal">Biochemistry. </span>2003;<span class="ref-vol">42</span>:6656–63.</span> [<a href="/pubmed/12779320" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12779320</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.hattori.2003.229">Hattori T, Takei Y, Koyama J, Nakazato M, Ikeda S. Clinical and pathological studies of cardiac amyloidosis in transthyretin type familial amyloid polyneuropathy. <span><span class="ref-journal">Amyloid. </span>2003;<span class="ref-vol">10</span>:229–39.</span> [<a href="/pubmed/14986482" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14986482</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.hellman.2008.181">Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pelli&#x000e9; C, Plant&#x000e9;-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. <span><span class="ref-journal">Amyloid. </span>2008;<span class="ref-vol">15</span>:181–6.</span> [<a href="/pmc/articles/PMC2738945/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2738945</span></a>] [<a href="/pubmed/18925456" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18925456</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.herlenius.2004.64">Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. <span><span class="ref-journal">Transplantation. </span>2004;<span class="ref-vol">77</span>:64–71.</span> [<a href="/pubmed/14724437" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14724437</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.holmgren.1994.351">Holmgren G, Costa PM, Andersson C, Asplund K, Steen L, Beckman L, Nylander PO, Teixeira A, Saraiva MJ, Costa PP. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. <span><span class="ref-journal">J Med Genet. </span>1994;<span class="ref-vol">31</span>:351–4.</span> [<a href="/pmc/articles/PMC1049863/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1049863</span></a>] [<a href="/pubmed/8064809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8064809</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.h_rnsten.2004.112">H&#x000f6;rnsten R, Wiklund U, Olofsson BO, Jensen SM, Suhr OB. Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type (ATTR Val30Met) patients. <span><span class="ref-journal">Transplantation. </span>2004;<span class="ref-vol">78</span>:112–6.</span> [<a href="/pubmed/15257048" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15257048</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.hund.2001.431">Hund E, Linke RP, Willig F, Grau A. Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">56</span>:431–5.</span> [<a href="/pubmed/11261421" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11261421</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.ikeda.2002.1001">Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. <span><span class="ref-journal">Neurology. </span>2002;<span class="ref-vol">58</span>:1001–7.</span> [<a href="/pubmed/11940682" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11940682</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.ikeda.1983.1055">Ikeda S, Oguchi K, Kobayashi S, Tsukahara S, Yanagisawa N. Histochemical study of rectal aminergic nerves in type I familial amyloid polyneuropathy. <span><span class="ref-journal">Neurology. </span>1983;<span class="ref-vol">33</span>:1055–8.</span> [<a href="/pubmed/6683801" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6683801</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.ikeda.2003.547">Ikeda S, Takei Y, Hashikura Y. Liver transplantation as treatment for neurological disorders. <span><span class="ref-journal">Expert Rev Neurother. </span>2003;<span class="ref-vol">3</span>:547–55.</span> [<a href="/pubmed/19810938" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19810938</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.ikeda.1997.618">Ikeda S, Takei Y, Yanagisawa N, Matsunami H, Hashikura Y, Ikegami T, Kawasaki S. Peripheral nerves regenerated in familial amyloid polyneuropathy after liver transplantation. <span><span class="ref-journal">Ann Intern Med. </span>1997;<span class="ref-vol">127</span>:618–20.</span> [<a href="/pubmed/9341060" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9341060</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.ikeda.1982.1364">Ikeda SI, Makishita H, Oguchi K, Yanagisawa N, Nagata T. Gastrointestinal amyloid deposition in familial amyloid polyneuropathy. <span><span class="ref-journal">Neurology. </span>1982;<span class="ref-vol">32</span>:1364–8.</span> [<a href="/pubmed/6890642" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6890642</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.jacob.2007.127">Jacob EK, Edwards WD, Zucker M, D'Cruz C, Seshan SV, Crow FW, Highsmith WE. Homozygous transthyretin mutation in an African American male. <span><span class="ref-journal">J Mol Diagn. </span>2007;<span class="ref-vol">9</span>:127–31.</span> [<a href="/pmc/articles/PMC1867428/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1867428</span></a>] [<a href="/pubmed/17251346" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17251346</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.jacobson.1990.127">Jacobson DR, Gorevic PD, Buxbaum JN. A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology. <span><span class="ref-journal">Am J Hum Genet. </span>1990;<span class="ref-vol">47</span>(1):127–36.</span> [<a href="/pmc/articles/PMC1683748/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1683748</span></a>] [<a href="/pubmed/2349941" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2349941</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.jacobson.1997.466">Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. <span><span class="ref-journal">N Engl J Med. </span>1997;<span class="ref-vol">336</span>:466–73.</span> [<a href="/pubmed/9017939" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9017939</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.jin.2004.1463">Jin K, Sato S, Takahashi T, Nakazaki H, Date Y, Nakazato M, Tominaga T, Itoyama Y, Ikeda S. Familial leptomeningeal amyloidosis with a transthyretin variant Asp18Gly representing repeated subarachnoid haemorrhages with superficial siderosis. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2004;<span class="ref-vol">75</span>:1463–6.</span> [<a href="/pmc/articles/PMC1738739/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1738739</span></a>] [<a href="/pubmed/15377697" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15377697</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.juneblad.2004.208">Juneblad K, Naslund A, Olofsson BO, Suhr OB. Outcome of exercise electrocardiography in familial amyloidotic polyneuropathy patients, Portuguese type, under evaluation for liver transplantation. <span><span class="ref-journal">Amyloid. </span>2004;<span class="ref-vol">11</span>:208–13.</span> [<a href="/pubmed/15523924" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15523924</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.kawaji.2004.257">Kawaji T, Ando Y, Ando E, Nakamura M, Hirata A, Tanihara H. A case of vitreous amyloidosis without systemic symptoms in familial amyloidotic polyneuropathy. <span><span class="ref-journal">Amyloid. </span>2004;<span class="ref-vol">11</span>:257–9.</span> [<a href="/pubmed/15678760" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15678760</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.kelly.1998.101">Kelly JW. The alternative conformations of amyloidogenic proteins and their multi- step assembly pathways. <span><span class="ref-journal">Curr Opin Struct Biol. </span>1998;<span class="ref-vol">8</span>:101–6.</span> [<a href="/pubmed/9519302" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9519302</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.koike.2004.129">Koike H, Misu K, Sugiura M, Iijima M, Mori K, Yamamoto M, Hattori N, Mukai E, Ando Y, Ikeda S, Sobue G. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. <span><span class="ref-journal">Neurology. </span>2004;<span class="ref-vol">63</span>:129–38.</span> [<a href="/pubmed/15249622" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15249622</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.llad_.2010.1386">Llad&#x000f3; L, Baliellas C, Casasnovas C, Ferrer I, Fabregat J, Ramos E, Castellote J, Torras J, Xiol X, Rafecas A. Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation. <span><span class="ref-journal">Liver Transpl. </span>2010;<span class="ref-vol">16</span>:1386–92.</span> [<a href="/pubmed/21117248" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21117248</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.lobato.2004.27">Lobato L, Beir&#x000e3;o I, Silva M, Fonseca I, Queiros J, Rocha G, Sarmento AM, Sousa A, Sequeiros J. End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors. <span><span class="ref-journal">Amyloid. </span>2004;<span class="ref-vol">11</span>:27–37.</span> [<a href="/pubmed/15185496" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15185496</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.maia.2015.159">Maia LF, Magalhaes R, Freitas J, Taipa R, Pires MM, Os&#x000f3;rio H, Dias D, Pessegueiro H, Correia M, Coelho T. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2015;<span class="ref-vol">86</span>:159–167.</span> [<a href="/pubmed/25091367" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25091367</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.mascalchi.1999.1498">Mascalchi M, Salvi F, Pirini MG, D'Errico A, Ferlini A, Lolli F, Plasmati R, Tessa C, Villari N, Tassinari CA. Transthyretin amyloidosis and superficial siderosis of the CNS. <span><span class="ref-journal">Neurology. </span>1999;<span class="ref-vol">53</span>:1498–503.</span> [<a href="/pubmed/10534258" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10534258</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.maurer.2018.1007">Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C, et al.  Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. <span><span class="ref-journal">N Engl J Med. </span>2018;<span class="ref-vol">379</span>:1007–16.</span> [<a href="/pubmed/30145929" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30145929</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.misu.1999.1951">Misu K, Hattori N, Nagamatsu M, Ikeda SI, Ando Y, Nakazato M, Takei Y, Hanyu N, Usui Y, Tanaka F, Harada T, Inukai A, Hashizume Y, Sobue G. Late-onset familial amyloid polyneuropathy type I (transthyretin Met30- associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. <span><span class="ref-journal">Brain. </span>1999;<span class="ref-vol">122</span>:1951–62.</span> [<a href="/pubmed/10506096" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10506096</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.mitsuhashi.2005.216">Mitsuhashi S, Yazaki M, Tokuda T, Sekijima Y, Washimi Y, Shimizu Y, Ando Y, Benson MD, Ikeda S. Biochemical characteristics of variant transthyretins causing hereditary leptomeningeal amyloidosis. <span><span class="ref-journal">Amyloid. </span>2005;<span class="ref-vol">12</span>:216–25.</span> [<a href="/pubmed/16399646" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16399646</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.mitsuhashi.2004.265">Mitsuhashi S, Yazaki M, Tokuda T, Yamamoto K, Ikeda S. MRI analysis on a patient with the V30M mutation is characteristic of leptomeningeal amyloid. <span><span class="ref-journal">Amyloid. </span>2004;<span class="ref-vol">11</span>:265–7.</span> [<a href="/pubmed/15678762" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15678762</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.mochizuki.2001.105">Mochizuki H, Kamakura K, Masaki T, Hirata A, Tokuda T, Yazaki M, Motoyoshi K, Ikeda S. Nodular cutaneous amyloidosis and carpal tunnel syndrome due to the amyloidogenic transthyretin His 114 variant. <span><span class="ref-journal">Amyloid. </span>2001;<span class="ref-vol">8</span>:105–10.</span> [<a href="/pubmed/11409031" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11409031</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.munarqu_s.2001.121">Munar-Qu&#x000e9;s M, Lopes Dominguez JM, Viader-Farre C, Moreira P, Saraiva MJ. Two Spanish sibs with familial amyloidotic polyneuropathy homozygous for the V30M-TTR gene. <span><span class="ref-journal">Amyloid. </span>2001;<span class="ref-vol">8</span>:121–3.</span> [<a href="/pubmed/11409034" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11409034</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.nakagawa.2016.58">Nakagawa M, Sekijima Y, Yazaki M, Tojo K, Yoshinaga T, Doden T, Koyama J, Yanagisawa S, Ikeda S. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. <span><span class="ref-journal">Amyloid. </span>2016;<span class="ref-vol">23</span>:58–63.</span> [<a href="/pubmed/26852880" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26852880</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.nakazato.1998.528">Nakazato M. Genotype-phenotype relationship in familial amyloid polyneuropathy. <span><span class="ref-journal">Neurol Med (Tokyo). </span>1998;<span class="ref-vol">48</span>:528–34.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.ng.2005.1425">Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. <span><span class="ref-journal">Arch Intern Med. </span>2005;<span class="ref-vol">165</span>:1425–9.</span> [<a href="/pubmed/15983293" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15983293</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.nichols.1991.175">Nichols WC, Liepnieks JJ, Snyder EL, Benson MD. Senile cardiac amyloidosis associated with homozygosity for a transthyretin variant (ILE-122). <span><span class="ref-journal">J Lab Clin Med. </span>1991;<span class="ref-vol">117</span>:175–80.</span> [<a href="/pubmed/2002274" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2002274</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.obayashi.2011.449">Obayashi K, Yamashita T, Tasaki M, Ueda M, Shono M, Jono H, Ohshima T, Ohya Y, Asonuma K, Inomata Y, Ando Y. Amyloid neuropathy in a younger domino liver transplanted recipient. <span><span class="ref-journal">Muscle Nerve. </span>2011;<span class="ref-vol">43</span>:449–50.</span> [<a href="/pubmed/21319169" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21319169</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.perfetto.2011.450">Perfetto F, Cappelli F, Bergesio F. Asymptomatic homozygous gene carrier in a family with Ile68Leu ATTR amyloidosis: a new endemic region in northern Tuscany? <span><span class="ref-journal">J Cardiovasc Med (Hagerstown). </span>2011;<span class="ref-vol">12</span>:450–1.</span> [<a href="/pubmed/21540676" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21540676</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.petersen.1997.307">Petersen RB, Goren H, Cohen M, Richardson SL, Tresser N, Lynn A, Gali M, Estes M, Gambetti P. Transthyretin amyloidosis: a new mutation associated with dementia. <span><span class="ref-journal">Ann Neurol. </span>1997;<span class="ref-vol">41</span>:307–13.</span> [<a href="/pubmed/9066351" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9066351</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.plant_bordeneuve.2003.e120">Plant&#x000e9;-Bordeneuve V, Carayol J, Ferreira A, Adams D, Clerget-Darpoux F, Misrahi M, Said G, Bona&#x000ef;ti-Pelli&#x000e9; C. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. <span><span class="ref-journal">J Med Genet. </span>2003;<span class="ref-vol">40</span>:e120.</span> [<a href="/pmc/articles/PMC1735318/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735318</span></a>] [<a href="/pubmed/14627687" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14627687</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.plant_bordeneuve.2007.693">Plant&#x000e9;-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, Said G. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). <span><span class="ref-journal">Neurology. </span>2007;<span class="ref-vol">69</span>:693–8.</span> [<a href="/pubmed/17698792" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17698792</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.plant_bordeneuve.1998.708">Plant&#x000e9;-Bordeneuve V, Lalu T, Misrahi M, Reilly MM, Adams D, Lacroix C, Said G. Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy. <span><span class="ref-journal">Neurology. </span>1998;<span class="ref-vol">51</span>:708–14.</span> [<a href="/pubmed/9748014" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9748014</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.rahbari.2016.126">Rahbari R, Wuster A, Lindsay SJ, Hardwick RJ, Alexandrov LB, Turki SA, Dominiczak A, Morris A, Porteous D, Smith B, Stratton MR, Hurles ME, et al.  Timing, rates and spectra of human germline mutation. <span><span class="ref-journal">Nat Genet. </span>2016;<span class="ref-vol">48</span>:126–33.</span> [<a href="/pmc/articles/PMC4731925/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4731925</span></a>] [<a href="/pubmed/26656846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26656846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.rochet.2000.60">Rochet JC, Lansbury PT Jr. Amyloid fibrillogenesis: themes and variations. <span><span class="ref-journal">Curr Opin Struct Biol. </span>2000;<span class="ref-vol">10</span>:60–8.</span> [<a href="/pubmed/10679462" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10679462</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.saraiva.2001.493">Saraiva MJ. Transthyretin mutations in hyperthyroxinemia and amyloid diseases. <span><span class="ref-journal">Hum Mutat. </span>2001;<span class="ref-vol">17</span>:493–503.</span> [<a href="/pubmed/11385707" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11385707</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.saraiva.2002.1">Saraiva MJ. Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies. <span><span class="ref-journal">Expert Rev Mol Med. </span>2002;<span class="ref-vol">4</span>:1–11.</span> [<a href="/pubmed/14987380" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14987380</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.sebasti_o.2001.733">Sebasti&#x000e3;o MP, Lamzin V, Saraiva MJ, Damas AM. Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution. <span><span class="ref-journal">J Mol Biol. </span>2001;<span class="ref-vol">306</span>:733–44.</span> [<a href="/pubmed/11243784" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11243784</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.sekijima.2015.1036">Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2015;<span class="ref-vol">86</span>:1036–43.</span> [<a href="/pubmed/25604431" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25604431</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.sekijima.2003.409">Sekijima Y, Hammarstrom P, Matsumura M, Shimizu Y, Iwata M, Tokuda T, Ikeda S, Kelly JW. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. <span><span class="ref-journal">Lab Invest. </span>2003;<span class="ref-vol">83</span>:409–17.</span> [<a href="/pubmed/12649341" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12649341</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.sekijima.2005.73">Sekijima Y, Wiseman RL, Matteson J, Hammarstrom P, Miller SR, Sawkar AR, Balch WE, Kelly JW. The biological and chemical basis for tissue-selective amyloid disease. <span><span class="ref-journal">Cell. </span>2005;<span class="ref-vol">121</span>:73–85.</span> [<a href="/pubmed/15820680" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15820680</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.sekijima.2016.773">Sekijima Y, Yazaki M, Oguchi K, Ezawa N, Yoshinaga T, Yamada M, Yahikozawa H, Watanabe M, Kametani F, Ikeda S. Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. <span><span class="ref-journal">Neurology. </span>2016;<span class="ref-vol">87</span>:773–81.</span> [<a href="/pubmed/27466465" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27466465</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.sekijima.2018.8">Sekijima Y, Yazaki M, Ueda M, Koike H, Yamada M, Ando Y. First nationwide survey on systemic wild-type ATTR amyloidosis in Japan. <span><span class="ref-journal">Amyloid. </span>2018;<span class="ref-vol">25</span>:8–10.</span> [<a href="/pubmed/29182024" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29182024</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.sipe.2016.209">Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. <span><span class="ref-journal">Amyloid. </span>2016;<span class="ref-vol">23</span>:209–13.</span> [<a href="/pubmed/27884064" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27884064</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.stangou.2004.615">Stangou AJ, Hawkins PN. Liver transplantation in transthyretin-related familial amyloid polyneuropathy. <span><span class="ref-journal">Curr Opin Neurol. </span>2004;<span class="ref-vol">17</span>:615–20.</span> [<a href="/pubmed/15367866" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15367866</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.stangou.1998.229">Stangou AJ, Hawkins PN, Heaton ND, Rela M, Monaghan M, Nihoyannopoulos P, O, Grady J, Pepys MB, Williams R. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy. implications for amyloid fibrillogenesis. <span><span class="ref-journal">Transplantation. </span>1998;<span class="ref-vol">66</span>:229.</span> [<a href="/pubmed/9701270" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9701270</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.stangou.2005.2356">Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. <span><span class="ref-journal">N Engl J Med. </span>2005;<span class="ref-vol">352</span>:2356.</span> [<a href="/pubmed/15930432" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15930432</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.stojkovic.2016.775">Stojkovic T. Hereditary neuropathies: an update. <span><span class="ref-journal">Rev Neurol (Paris). </span>2016;<span class="ref-vol">172</span>:775–8.</span> [<a href="/pubmed/27866730" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27866730</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.takei.1999.592">Takei Y, Ikeda S, Hashikura Y, Ikegami T, Kawasaki S. Partial-liver transplantation to treat familial amyloid polyneuropathy: follow-up of 11 patients. <span><span class="ref-journal">Ann Intern Med. </span>1999;<span class="ref-vol">131</span>:592–5.</span> [<a href="/pubmed/10523220" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10523220</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.tojo.2008.796">Tojo K, Sekijima Y, Machida K, Tsuchiya A, Yazaki M, Ikeda S. Amyloidogenic transthyretin Val30Met homozygote showing unusually early-onset familial amyloid polyneuropathy. <span><span class="ref-journal">Muscle Nerve. </span>2008;<span class="ref-vol">37</span>:796–803.</span> [<a href="/pubmed/18506713" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18506713</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.ueda.2011.1533">Ueda M, Horibata Y, Shono M, Misumi Y, Oshima T, Su Y, Tasaki M, Shinriki S, Kawahara S, Jono H, Obayashi K, Ogawa H, Ando Y. Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study. <span><span class="ref-journal">Mod Pathol. </span>2011;<span class="ref-vol">24</span>:1533–44.</span> [<a href="/pubmed/21822203" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21822203</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.uemichi.1999.1152">Uemichi T, Uitti RJ, Koeppen AH, Donat JR, Benson MD. Oculoleptomeningeal amyloidosis associated with a new transthyretin variant Ser64. <span><span class="ref-journal">Arch Neurol. </span>1999;<span class="ref-vol">56</span>:1152–5.</span> [<a href="/pubmed/10488818" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10488818</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.vita.2005.259">Vita G, Mazzeo A, Di Leo R, Ferlini A. Recurrent syncope as persistently isolated feature of transthyretin amyloidotic polyneuropathy. <span><span class="ref-journal">Neuromuscul Disord. </span>2005;<span class="ref-vol">15</span>:259–61.</span> [<a href="/pubmed/15725588" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15725588</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.vital.2004.232">Vital C, Vital A, Bouillot-Eimer S, Brechenmacher C, Ferrer X, Lagueny A. Amyloid neuropathy: a retrospective study of 35 peripheral nerve biopsies. <span><span class="ref-journal">J Peripher Nerv Syst. </span>2004;<span class="ref-vol">9</span>:232–41.</span> [<a href="/pubmed/15574136" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15574136</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.westermark.2003.48">Westermark P, Bergstrom J, Solomon A, Murphy C, Sletten K. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. <span><span class="ref-journal">Amyloid. </span>2003;<span class="ref-vol">10</span> Suppl 1:48–54.</span> [<a href="/pubmed/14640042" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14640042</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.yamamoto.2007.2597">Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksanen A, Iwata T, Gjertsen H, Soderdahl G, Wikstrom L, Ando Y, Suhr OB, Ericzon BG. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. <span><span class="ref-journal">Am J Transplant. </span>2007;<span class="ref-vol">7</span>:2597–604.</span> [<a href="/pubmed/17868062" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17868062</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.yamashita.2005.127">Yamashita T, Asl KH, Yazaki M, Benson MD. A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. <span><span class="ref-journal">Amyloid. </span>2005;<span class="ref-vol">12</span>:127–30.</span> [<a href="/pubmed/16011990" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16011990</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.yazaki.2002.263">Yazaki M, Connors LH, Eagle RC Jr, Leff SR, Skinner M, Benson MD. Transthyretin amyloidosis associated with a novel variant (Trp41Leu) presenting with vitreous opacities. <span><span class="ref-journal">Amyloid. </span>2002;<span class="ref-vol">9</span>:263–7.</span> [<a href="/pubmed/12557756" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12557756</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.yazaki.a">Yazaki M, Take YI, Katoh M, Ikeda SI (2000a) Postmortem findings in two familial amyloidosis patients with transthyretin variant Asp38Ala. Amyloid. 7:270-7. [<a href="/pubmed/11132096" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11132096</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.yazaki.2000b.702">Yazaki M, Tokuda T, Nakamura A, Higashikata T, Koyama J, Higuchi K, Harihara Y, Baba S, Kametani F, Ikeda S. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>2000b;<span class="ref-vol">274</span>:702–6.</span> [<a href="/pubmed/10924339" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10924339</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfap.REF.yoshinaga.2004.56">Yoshinaga T, Takei Y, Katayanagi K, Ikeda S. Postmortem findings in a familial amyloid polyneuropathy patient with homozygosity of the mutant Val30Met transthyretin gene. <span><span class="ref-journal">Amyloid. </span>2004;<span class="ref-vol">11</span>:56–60.</span> [<a href="/pubmed/15185500" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15185500</span></a>]</div></li></ul></div></div><div id="tfap.Chapter_Notes"><h2 id="_tfap_Chapter_Notes_">Chapter Notes</h2><div id="tfap.Author_History"><h3>Author History</h3><p>Shu-ichi Ikeda, MD, PhD; Shinsu University Hospital (2001-2018)<br />Yoshiki Sekijima, MD, PhD (2006-present)<br />Takahiko Tokuda, MD, PhD; Kyoto Prefectural University Hospital (2001-2018)<br />Kunihiro Yoshida, MD, PhD; Shinsu University Hospital (2001-2018)</p></div><div id="tfap.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>20 December 2018 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 January 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 September 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 March 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>2 March 2005 (cd) Revision: mutation scanning and sequencing of select exons no longer clinically available</div></li><li class="half_rhythm"><div>5 March 2004 (ky) Revision: <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a></div></li><li class="half_rhythm"><div>9 January 2004 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 November 2001 (me) Review posted live</div></li><li class="half_rhythm"><div>25 June 2001 (ky) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1194</span><span class="label">PMID: <a href="/pubmed/20301373" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301373</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/hsp/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/hyperek/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1194&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1194/?report=reader">PubReader</a></li><li><a href="/books/NBK1194/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1194" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1194" style="display:none" title="Cite this Page"><div class="bk_tt">Sekijima Y. Hereditary Transthyretin Amyloidosis. 2001 Nov 5 [Updated 2018 Dec 20]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1194/pdf/Bookshelf_NBK1194.pdf">PDF version of this page</a> (588K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#tfap.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#tfap.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#tfap.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#tfap.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#tfap.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#tfap.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#tfap.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#tfap.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#tfap.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#tfap.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#tfap.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#tfap.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7276[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TTR</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1473892" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1473892" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1473892" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1473892" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29343286" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.</a><span class="source">[Orphanet J Rare Dis. 2018]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2018 Jan 17; 13(1):6. Epub 2018 Jan 17.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25228988" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Recent advances in transthyretin amyloidosis therapy.</a><span class="source">[Transl Neurodegener. 2014]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Recent advances in transthyretin amyloidosis therapy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ueda M, Ando Y. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Transl Neurodegener. 2014; 3:19. Epub 2014 Sep 13.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25604431" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.</a><span class="source">[J Neurol Neurosurg Psychiatry....]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sekijima Y. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Neurol Neurosurg Psychiatry. 2015 Sep; 86(9):1036-43. Epub 2015 Jan 20.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30595768" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">A rare variant of transthyretin-related amyloidosis associated with exclusive cardiomyopathy in a Hong Kong Chinese patient.</a><span class="source">[J Cardiol Cases. 2018]</span><div class="brieflinkpop offscreen_noflow">A rare variant of transthyretin-related amyloidosis associated with exclusive cardiomyopathy in a Hong Kong Chinese patient.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wong CW, Ng WY, So KL, Chan YH, Yip SF, Mak CM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Cardiol Cases. 2018 Dec; 18(6):185-188. Epub 2018 Oct 22.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23776379" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis.</a><span class="source">[Appl Clin Genet. 2012]</span><div class="brieflinkpop offscreen_noflow">Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hund E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Appl Clin Genet. 2012; 5:37-41. Epub 2012 Jun 18.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301373" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301373" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041397dd21425a25c89c1c">Hereditary Transthyretin Amyloidosis - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Hereditary Transthyretin Amyloidosis - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:57:43-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE88EA39E03FE36100000000087602C7&amp;ncbi_session=CE88EA39E0413961_2166SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1194%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1194&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1194/&amp;ncbi_pagename=Hereditary Transthyretin Amyloidosis - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88EA39E0413961_2166SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>